

American Cancer Society, American Society for Colposcopy
American Society for Clinical Pathology screening guide
detection of cervical cancer

Ca-A Cancer Journal for Clinicians

62, 147-172

DOI: [10.3322/caac.21139](https://doi.org/10.3322/caac.21139)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Sexually Transmitted Diseases Treatment Guidelines, 2010. <i>Annals of Emergency Medicine</i> , 2011, 58, 67-68.	0.6	925
2	Clinical Human Papillomavirus Detection Forecasts Cervical Cancer Risk in Women Over 18 Years of Follow-Up. <i>Journal of Clinical Oncology</i> , 2012, 30, 3044-3050.	1.6	87
3	Lung Carcinoma in the Era of Personalized Medicine: The Role of Cytology. <i>Acta Cytologica</i> , 2012, 56, 587-589.	1.3	4
4	Revised Terminology for Cervical Histopathology and Its Implications for Management of High-Grade Squamous Intraepithelial Lesions of the Cervix. <i>Obstetrics and Gynecology</i> , 2012, 120, 1465-1471.	2.4	132
5	Negative Predictive Value of Pap Testing. <i>Obstetrics and Gynecology</i> , 2012, 120, 791-797.	2.4	17
6	Introduction of Human Papillomavirus DNA Screening in the World: 15 Years of Experience. <i>Vaccine</i> , 2012, 30, F117-F122.	3.8	64
7	Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical Cancer. <i>Vaccine</i> , 2012, 30, F88-F99.	3.8	695
8	Performance of p16/Ki-67 Immunostaining to Detect Cervical Cancer Precursors in a Colposcopy Referral Population. <i>Clinical Cancer Research</i> , 2012, 18, 4154-4162.	7.0	196
9	Age-specific trends in black–white disparities in cervical cancer incidence in the United States: 1975–2009. <i>Gynecologic Oncology</i> , 2012, 127, 611-615.	1.4	45
10	Optimizing cervical cancer prevention strategies in the United States. <i>Gynecologic Oncology</i> , 2012, 127, 437-439.	1.4	1
11	Towards more eclectic evidence-based medicine in cancer prevention and control. <i>Preventive Medicine</i> , 2012, 55, 552-553.	3.4	3
12	Laboratory and clinical aspects of human papillomavirus testing. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2012, 49, 117-136.	6.1	37
13	Caregiving associated with selected cancer risk behaviors and screening utilization among women: cross-sectional results of the 2009 BRFSS. <i>BMC Public Health</i> , 2012, 12, 685.	2.9	30
14	Cancer-related risk factors and preventive measures in US Hispanics/Latinos. <i>Ca-A Cancer Journal for Clinicians</i> , 2012, 62, 353-363.	329.8	46
15	Thinking Differently About Cervical Cancer Screening in High-Risk Populations. <i>American Journal of Preventive Medicine</i> , 2012, 43, 221-224.	3.0	3
16	Human papillomavirus DNA detection in women with normal and abnormal cervical Pap cytology. <i>Diagnostic Histopathology</i> , 2012, 18, 341-347.	0.4	2
17	New cervical cancer screening guidelines published. <i>Cancer</i> , 2012, 118, 2565-2565.	4.1	0
18	Screening history preceding a diagnosis of cervical cancer in women age 65 and older. <i>Gynecologic Oncology</i> , 2012, 126, 203-206.	1.4	32

#	ARTICLE	IF	CITATIONS
19	Physician characteristics and beliefs associated with use of pelvic examinations in asymptomatic women. Preventive Medicine, 2012, 54, 415-421.	3.4	37
20	HPV-based Tests for Cervical Cancer Screening and Management of Cervical Disease. Current Obstetrics and Gynecology Reports, 2013, 2, 76-85.	0.8	15
21	Recommendations for a national agenda to substantially reduce cervical cancer. Cancer Causes and Control, 2013, 24, 1583-1593.	1.8	19
22	Human Papillomavirus in Solid Organ Transplantation. American Journal of Transplantation, 2013, 13, 189-200.	4.7	24
23	A systematic review of randomized trials assessing human papillomavirus testing in cervical cancer screening. American Journal of Obstetrics and Gynecology, 2013, 208, 343-353.	1.3	27
24	Human papillomavirus genotypes detected in clinician-collected and self-collected specimens from women living in the Mississippi Delta. BMC Infectious Diseases, 2013, 13, 5.	2.9	13
25	Prevention of human papillomavirus-related diseases: Impediments to progress. Preventive Medicine, 2013, 57, 407-408.	3.4	4
26	The Modern Cytology Laboratory. Obstetrics and Gynecology Clinics of North America, 2013, 40, 199-210.	1.9	5
27	LSIL. Obstetrics and Gynecology Clinics of North America, 2013, 40, 283-289.	1.9	3
28	HPV genotype distribution according to severity of cervical neoplasia using the digene HPV genotyping LQ test. Archives of Virology, 2013, 158, 1143-1149.	2.1	9
29	The Impact of Genomics on Oncology Nursing. Nursing Clinics of North America, 2013, 48, 585-626.	1.5	8
30	College Sorority Members' Knowledge and Behaviors Regarding Human Papillomavirus and Cervical Cancer. Nursing Clinics of North America, 2013, 48, 215-227.	1.5	7
31	Cervical Cancer Screening in Pregnancy. Obstetrics and Gynecology Clinics of North America, 2013, 40, 269-282.	1.9	22
32	Early detection of high-grade squamous intraepithelial lesions in the cervix with quantitative spectroscopic imaging. Journal of Biomedical Optics, 2013, 18, 076013.	2.6	2
33	Human Papillomavirus Infection and the Multistage Carcinogenesis of Cervical Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 553-560.	2.5	223
34	Patterns of persistent genital human papillomavirus infection among women worldwide: A literature review and meta-analysis. International Journal of Cancer, 2013, 133, 1271-1285.	5.1	171
35	Prevalence of human papillomavirus infection and genotype distribution determined by the cyclic-catcher melting temperature analysis in Korean medical checkup population. Journal of Microbiology, 2013, 51, 665-670.	2.8	6
36	Impact of Human Papillomavirus Vaccination on Cervical Cytology Screening, Colposcopy, and Treatment. American Journal of Epidemiology, 2013, 178, 752-760.	3.4	26

#	ARTICLE	IF	CITATIONS
37	Risk of Precancer Determined by HPV Genotype Combinations in Women with Minor Cytologic Abnormalities. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1095-1101.	2.5	24
38	Efficacy of screening in preventing cervical cancer among older women. <i>Cancer Causes and Control</i> , 2013, 24, 1653-1660.	1.8	38
39	Cervical-Cancer Screening with Human Papillomavirus and Cytologic Cotesting. <i>New England Journal of Medicine</i> , 2013, 369, 2324-2331.	27.0	102
40	Cervical cancer screening among Michigan women: â€˜The Special Cancer Behavioral Risk Factor Surveyâ€™™, 2004â€˜2008. <i>Journal of Obstetrics and Gynaecology</i> , 2013, 33, 617-621.	0.9	0
41	AMIGAS: Building a Cervical Cancer Screening Intervention for Public Health Practice. <i>Journal of Women's Health</i> , 2013, 22, 718-723.	3.3	13
42	Significant association between CYP1A1 T3801C polymorphism and cervical neoplasia risk: a systematic review and meta-analysis. <i>Tumor Biology</i> , 2013, 34, 223-230.	1.8	14
43	<i>Pseudomonas aeruginosa</i> serology and risk for re-isolation in the EPIC trial. <i>Journal of Cystic Fibrosis</i> , 2013, 12, 147-153.	0.7	30
44	Tailored telephone counseling to improve adherence to follow-up regimens after an abnormal pap smear among minority, underserved women. <i>Patient Education and Counseling</i> , 2013, 93, 488-495.	2.2	29
45	Cost-Effectiveness Of Various Combinations Of Human Papillomavirus (Hpv)-Based Testing, Including Genotyping For Hpv 16/18, For Cervical Cancer Screening. <i>Value in Health</i> , 2013, 16, A142-A143.	0.3	2
46	Clear cell adenocarcinoma of the uterine cervix in an 18 year-old pregnant female. <i>Gynecologic Oncology Case Reports</i> , 2013, 5, 49-51.	0.9	1
47	Profilaktyka raka szyjki macicy â€˜problem interdyscyplinarny. Czy i jak moÅ¼emy poprawiÄŝ sytuacjÄ™™ w Polsce?. <i>Pediatrica Polska</i> , 2013, 88, 340-346.	0.2	2
48	Performance and Reproducibility of Gynecologic Cytology Interpretation Using the FocalPoint System. <i>American Journal of Clinical Pathology</i> , 2013, 140, 567-571.	0.7	15
49	Multimodal hyperspectroscopy as a triage test for cervical neoplasia: Pivotal clinical trial results. <i>Gynecologic Oncology</i> , 2013, 130, 147-151.	1.4	12
50	Screening Adolescents and Young Women. <i>Obstetrics and Gynecology Clinics of North America</i> , 2013, 40, 257-268.	1.9	10
51	APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 208, 144.e1-144.e8.	1.3	53
52	Human Papillomavirus Testing in Cervical Cancer Screening. <i>Obstetrics and Gynecology Clinics of North America</i> , 2013, 40, 377-390.	1.9	13
53	HPV and cervical cancer prevention update. <i>Contraception</i> , 2013, 88, 299.	1.5	0
54	Discussion: â€˜Comparison of cervical cancer screening strategies,' by Cox et al. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 208, e1-e4.	1.3	1

#	ARTICLE	IF	CITATIONS
55	Discussing the diagnosis of HPV-OSCC: Common questions and answers. Oral Oncology, 2013, 49, 863-871.	1.5	71
56	Triage of HPV-positive women in cervical cancer screening. Lancet Oncology, The, 2013, 14, 107-109.	10.7	32
57	Counseling the Patient with HPV Disease. Obstetrics and Gynecology Clinics of North America, 2013, 40, 391-402.	1.9	8
58	Cervical Cancer Screening Guidelines 2012. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 2013, 42, 1-2.	0.5	2
59	Cancer screening in the United States, 2013. Ca-A Cancer Journal for Clinicians, 2013, 63, 87-105.	329.8	249
60	Accurate human papillomavirus genotyping by 454 pyrosequencing. Clinical Microbiology and Infection, 2013, 19, E428-E434.	6.0	21
61	What is lacking in current decision aids on cancer screening?. Ca-A Cancer Journal for Clinicians, 2013, 63, 193-214.	329.8	58
62	The Natural History of Cervical Human Papillomavirus Infections and Cervical Cancer. Obstetrics and Gynecology Clinics of North America, 2013, 40, 165-176.	1.9	38
63	The four steps in the prevention of human papillomavirus-associated neoplasia. Archives of Gynecology and Obstetrics, 2013, 288, 979-988.	1.7	4
64	Consensus recommendations for the prevention of cervical cancer in sub-Saharan Africa. Southern African Journal of Gynaecological Oncology, 2013, 5, 47-57.	0.3	4
65	Cervical cancer screening programme in Limpopo province: January 2007 to December 2010. Southern African Journal of Gynaecological Oncology, 2013, 5, 4-10.	0.3	4
66	New Strategies for Human Papillomavirus-Based Cervical Screening. Women's Health, 2013, 9, 443-452.	1.5	26
67	Age-Specific Occurrence of HPV16- and HPV18-Related Cervical Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1313-1318.	2.5	38
68	The Clinical Role of HPV Testing in Primary and Secondary Cervical Cancer Screening. Obstetrics and Gynecology International, 2013, 2013, 1-7.	1.3	23
69	Screening for Cervical Cancer in Low-Resource Settings in 2011. Archives of Pathology and Laboratory Medicine, 2013, 137, 782-790.	2.5	9
70	Prevention of human papillomavirus-related malignancy: Access is the answer. Cancer, 2013, 119, 2953-2955.	4.1	1
71	2012 Cervical Cancer Screening Guidelines and the Future Role of HPV Testing. Clinical Obstetrics and Gynecology, 2013, 56, 44-50.	1.1	32
72	Cost-effectiveness of Cervical Cancer Prevention. Clinical Obstetrics and Gynecology, 2013, 56, 55-64.	1.1	9

#	ARTICLE	IF	CITATIONS
73	2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Journal of Lower Genital Tract Disease, 2013, 17, S1-S27.	1.9	614
74	Five-Year Risks of CIN 3+ and Cervical Cancer Among Women With HPV Testing of ASC-US Pap Results. Journal of Lower Genital Tract Disease, 2013, 17, S36-S42.	1.9	85
75	Counterpoint: Cervical Cancer Screening Guidelines--Approaching the Golden Age. American Journal of Epidemiology, 2013, 178, 1023-1026.	3.4	15
76	An Evaluation of Novel, Lower-Cost Molecular Screening Tests for Human Papillomavirus in Rural China. Cancer Prevention Research, 2013, 6, 938-948.	1.5	88
77	Current Recommendations for Cervical Cancer Screening: Do They Render the Annual Pelvic Examination Obsolete?. Medical Principles and Practice, 2013, 22, 313-322.	2.4	19
78	Drowsy Driving—19 States and the District of Columbia, 2009-2010. JAMA - Journal of the American Medical Association, 2013, 309, 760.	7.4	7
79	Swimming Upstream: Doing Less in Health Care Is Hard. JAMA Internal Medicine, 2013, 173, 856.	5.1	9
80	Negative Biopsy Specimens in the Setting of High A Priori Probability of Disease. American Journal of Clinical Pathology, 2013, 139, 418-420.	0.7	1
81	Cervical Cancer Screening Among Young Adult Women in the United States. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 580-588.	2.5	22
82	Abnormal Cytology in 2012. Clinical Obstetrics and Gynecology, 2013, 56, 25-34.	1.1	8
83	Point: Cervical Cancer Screening Guidelines Should Consider Observational Data on Screening Efficacy in Older Women. American Journal of Epidemiology, 2013, 178, 1020-1022.	3.4	17
84	Prevalence of high-risk human papilloma virus among women with hepatitis C virus before liver transplantation. Transplant Infectious Disease, 2013, 15, 400-404.	1.7	9
85	A Comparison of Human Papillomavirus Genotype-Specific DNA and E6/E7 mRNA Detection to Identify Anal Precancer among HIV-Infected Men Who Have Sex with Men. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 42-49.	2.5	23
86	Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels. Journal of the National Cancer Institute, 2013, 105, 175-201.	6.3	886
87	Factors Associated With Adherence to Follow-up Colposcopy. American Journal of Health Education, 2013, 44, 293-298.	0.6	25
88	The Impact of a Culturally Tailored Patient Navigator Program on Cervical Cancer Prevention in Latina Women. Journal of Women's Health, 2013, 22, 426-431.	3.3	32
89	Screening for gynecological cancers. Expert Review of Obstetrics and Gynecology, 2013, 8, 143-160.	0.4	1
91	Minimizing unnecessary colposcopies and biopsies. Nurse Practitioner, 2013, 38, 11-13.	0.3	0

#	ARTICLE	IF	CITATIONS
92	Practice Bulletin No. 140. Obstetrics and Gynecology, 2013, 122, 1338-1366.	2.4	82
93	2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Obstetrics and Gynecology, 2013, 121, 829-846.	2.4	617
94	Optimal Interval for Routine Cytologic Screening in the United States. JAMA Internal Medicine, 2013, 173, 241.	5.1	6
95	Major clinical research advances in gynecologic cancer in 2012. Journal of Gynecologic Oncology, 2013, 24, 66.	2.2	36
96	Updates of the current screening guidelines for the early detection of cervical cancer. Journal of Gynecologic Oncology, 2013, 24, 212.	2.2	0
97	Molecular Tools for Detection Human Papillomavirus. , 0, , .		0
98	Utilization of Human papillomavirus (HPV) DNA detection for cervical cancer screening in developing countries: A myth or reality. African Journal of Microbiology Research, 2013, 7, 2135-2139.	0.4	4
99	Targeting Human Papillomavirus to Reduce the Burden of Cervical, Vulvar and Vaginal Cancer and Pre-Invasive Neoplasia: Establishing the Baseline for Surveillance. PLoS ONE, 2014, 9, e88323.	2.5	38
100	Intent to Participate in Future Cervical Cancer Screenings Is Lower when Satisfaction with the Decision to Be Vaccinated Is Neutral. PLoS ONE, 2014, 9, e98665.	2.5	5
101	The Road Ahead for Cervical Cancer Prevention and Control. Current Oncology, 2014, 21, 255-264.	2.2	41
102	Cervical premalignant lesions and their management. Journal of the Turkish German Gynecology Association, 2014, 15, 109-121.	0.6	25
103	Update on prevention and screening of cervical cancer. World Journal of Clinical Oncology, 2014, 5, 744.	2.3	93
104	Comparative effectiveness study on human papillomavirus detection methods used in the cervical cancer screening programme. BMJ Open, 2014, 4, e003460.	1.9	20
105	The low risk of precancer after a screening result of human papillomavirus negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management. Cancer Cytopathology, 2014, 122, 842-850.	2.4	25
107	Overview of the CDC Cervical Cancer (Cx3) Study: An Educational Intervention of HPV Testing for Cervical Cancer Screening. Journal of Women's Health, 2014, 23, 197-203.	3.3	15
108	Perceptions of Dyspareunia in Postmenopausal Women with Vulvar and Vaginal Atrophy: Findings from the Revive Survey. Women's Health, 2014, 10, 445-454.	1.5	13
109	Benefits and harms of cervical screening from age 20 years compared with screening from age 25 years. British Journal of Cancer, 2014, 110, 1841-1846.	6.4	38
110	Comparison of the Aptima and Cervista Tests for Detection of High-Risk Human Papillomavirus in Cervical Cytology Specimens. American Journal of Clinical Pathology, 2014, 142, 561-566.	0.7	11

#	ARTICLE	IF	CITATIONS
111	Cervical Cancer Screening Outcomes in a Refugee Population. <i>Journal of Immigrant and Refugee Studies</i> , 2014, 12, 1-8.	1.7	9
112	Positive High-Risk HPV Test with Negative Cytology—A Conundrum and Blessing of Our Latest Technology. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 10-11.	2.5	0
113	Cervical Screening at Age 50–64 Years and the Risk of Cervical Cancer at Age 65 Years and Older: Population-Based Case Control Study. <i>PLoS Medicine</i> , 2014, 11, e1001585.	8.4	104
114	Methylation of Twelve CpGs in Human Papillomavirus Type 16 (HPV16) as an Informative Biomarker for the Triage of Women Positive for HPV16 Infection. <i>Cancer Prevention Research</i> , 2014, 7, 526-533.	1.5	13
115	Invited Commentary: Multiple Human Papillomavirus Infections and Type Replacement—Anticipating the Future After Human Papillomavirus Vaccination. <i>American Journal of Epidemiology</i> , 2014, 180, 1076-1081.	3.4	11
116	The Interpretation of LSIL-H. <i>American Journal of Clinical Pathology</i> , 2014, 142, 278-279.	0.7	4
117	Cervical Cancer Screening in Older Women: New Evidence and Knowledge Gaps. <i>PLoS Medicine</i> , 2014, 11, e1001586.	8.4	9
119	Segmentation and Splitting of Touching Vaginal Bacteria Based on Superpixel and Effective Distance. , 2014, , .		1
120	“I don't care whether it's HPV or <scp>ABC</scp>, I just want to know if I have cancer.” Factors influencing women's emotional responses to undergoing human papillomavirus testing in routine management in cervical screening: a qualitative study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2014, 121, 1421-1430.	2.3	38
121	Increased age and race-specific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000 to 2009. <i>Cancer</i> , 2014, 120, 2032-2038.	4.1	127
122	Public health national approach to reducing breast and cervical cancer disparities. <i>Cancer</i> , 2014, 120, 2537-2539.	4.1	33
123	The concordance of HPV DNA detection by Hybrid Capture 2 and careHPV on clinician- and self-collected specimens. <i>Journal of Clinical Virology</i> , 2014, 61, 553-557.	3.1	13
124	Whole-body magnetic resonance imaging (WB-MRI) as surveillance for subsequent malignancies in survivors of hereditary retinoblastoma: A pilot study. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1440-1444.	1.5	59
125	Prognostic scores after surgical treatment for cervical intraepithelial neoplasia: a proposed model and possible implications for postoperative follow-up. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2014, 93, 941-948.	2.8	9
126	The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States. <i>International Journal of Cancer</i> , 2014, 135, 624-634.	5.1	36
127	Can the New Cervical Cancer Screening and Management Guidelines Be Simplified?. <i>JAMA Internal Medicine</i> , 2014, 174, 1029.	5.1	8
128	Detection of Cervical Cancer Biomarker Patterns in Blood Plasma and Urine by Differential Scanning Calorimetry and Mass Spectrometry. <i>PLoS ONE</i> , 2014, 9, e84710.	2.5	59
129	Choosing a Screening Method for Cervical Cancer. <i>JAMA Internal Medicine</i> , 2014, 174, 1027.	5.1	6

#	ARTICLE	IF	CITATIONS
130	Current Cervical Cancer Screening Knowledge, Awareness, and Practices Among U.S. Affiliated Pacific Island Providers: Opportunities and Challenges. <i>Oncologist</i> , 2014, 19, 383-393.	3.7	22
131	cobas [®] 4800 HPV Test, a real-time polymerase chain reaction assay for the detection of human papillomavirus in cervical specimens. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 5-16.	3.1	21
132	Microinvasive Adenocarcinoma of the Cervix in a Young Woman Vaccinated Against Human Papillomavirus. <i>Journal of Lower Genital Tract Disease</i> , 2014, 18, E50-E54.	1.9	2
133	Cervical Cancer Screening. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2279.	7.4	5
134	Cervical Cancer Rates After the Transition From Annual Pap to 3-Year HPV and Pap. <i>Journal of Lower Genital Tract Disease</i> , 2014, 18, 57-60.	1.9	12
135	Response. <i>Journal of the National Cancer Institute</i> , 2014, 107, dju390-dju390.	6.3	0
136	Fluorescence In Situ Hybridization Testing for the Diagnosis of High-Grade Cervical Abnormalities. <i>Journal of Lower Genital Tract Disease</i> , 2014, 18, 218-227.	1.9	7
137	Abnormal Pap Tests and Human Papillomavirus Infections Among HIV-Infected and Uninfected Women Who Have Sex With Women. <i>Journal of Lower Genital Tract Disease</i> , 2014, 18, 50-56.	1.9	12
138	Three-Year Risk of Cervical Precancer and Cancer After the Detection of Low-Risk Human Papillomavirus Genotypes Targeted by a Commercial Test. <i>Obstetrics and Gynecology</i> , 2014, 123, 49-56.	2.4	9
139	Analytic and Clinical Performance of cobas HPV Testing in Anal Specimens from HIV-Positive Men Who Have Sex with Men. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2892-2897.	3.9	29
140	National Trends and Disparities in Cervical Cancer Screening among Commercially Insured Women, 2001-2010. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2366-2373.	2.5	20
141	Cancer Screening Rates in Individuals With Different Life Expectancies. <i>JAMA Internal Medicine</i> , 2014, 174, 1558.	5.1	142
142	Expression of Yes-Associated Protein in Cervical Squamous Epithelium Lesions. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1575-1582.	2.5	25
143	Six1 promotes epithelial-mesenchymal transition and malignant conversion in human papillomavirus type 16-immortalized human keratinocytes. <i>Carcinogenesis</i> , 2014, 35, 1379-1388.	2.8	36
144	Cervical excisional treatment of young women: A population-based study. <i>Gynecologic Oncology</i> , 2014, 132, 628-635.	1.4	17
145	Chemoprevention of colonic aberrant crypt foci by <i>Gynura procumbens</i> in rats. <i>Journal of Ethnopharmacology</i> , 2014, 151, 1194-1201.	4.1	35
146	Ancillary Diagnostics in Gynecologic Cytology. <i>Surgical Pathology Clinics</i> , 2014, 7, 89-103.	1.7	0
147	HPV self-testing and cervical cancer screening coverage. <i>Lancet Oncology</i> , The, 2014, 15, 128-129.	10.7	18

#	ARTICLE	IF	CITATIONS
149	Virus Infection and Human Cancer: An Overview. Recent Results in Cancer Research, 2014, 193, 1-10.	1.8	62
150	Population-based surveillance for cervical cancer precursors in three central cancer registries, United States 2009. Cancer Causes and Control, 2014, 25, 571-581.	1.8	15
151	Role of Human Papillomavirus Testing in Screening of Cervical Neoplasia. Current Obstetrics and Gynecology Reports, 2014, 3, 116-122.	0.8	1
152	Does Knowledge Influence Pap Test Screening Among Young African-American Women?. Journal of Cancer Education, 2014, 29, 478-481.	1.3	10
153	Impact of Electronic Documentation on Pap Screening Rates in an Urban Health Center. Journal of Community Health, 2014, 39, 416-422.	3.8	1
154	Is HPV DNA testing specificity comparable to that of cytological testing in primary cervical cancer screening? Results of a meta-analysis of randomized controlled trials. International Journal of Cancer, 2014, 135, 166-177.	5.1	39
155	Cancer screening in the United States, 2014: A review of current American Cancer Society guidelines and current issues in cancer screening. Ca-A Cancer Journal for Clinicians, 2014, 64, 30-51.	329.8	167
156	Molecular targets of HPV oncoproteins: Potential biomarkers for cervical carcinogenesis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1845, 91-103.	7.4	38
157	2013 statement on human papillomavirus DNA test utilization. Diagnostic Cytopathology, 2014, 42, 449-452.	1.0	0
158	Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncology, 2014, 50, 380-386.	1.5	388
159	Current practice patterns in cervical cancer screening in Indiana. American Journal of Obstetrics and Gynecology, 2014, 210, 265.e1-265.e8.	1.3	15
160	Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncology, The, 2014, 15, 172-183.	10.7	508
161	HPV testing with cytology triage for cervical cancer screening in routine practice. American Journal of Obstetrics and Gynecology, 2014, 210, 474.e1-474.e7.	1.3	21
162	Influence of qualitative research on women's health screening guidelines. American Journal of Obstetrics and Gynecology, 2014, 210, 44.e1-44.e6.	1.3	8
163	Comparison of Human Papillomavirus Detections in Urine, Vulvar, and Cervical Samples from Women Attending a Colposcopy Clinic. Journal of Clinical Microbiology, 2014, 52, 187-192.	3.9	37
164	Human papillomavirus testing and cytologic/histopathologic â€œtest of cureâ€œ follow-up results after excisional treatment for high-grade cervical intraepithelial neoplasia. Journal of the American Society of Cytopathology, 2014, 3, 15-20.	0.5	5
165	Lower cost strategies for triage of human papillomavirus DNAâ€œpositive women. International Journal of Cancer, 2014, 134, 2891-2901.	5.1	80
166	Pap Test Use Is Lower Among Female-to-Male Patients Than Non-Transgender Women. American Journal of Preventive Medicine, 2014, 47, 808-812.	3.0	161

#	ARTICLE	IF	CITATIONS
167	Automation-assisted cervical cancer screening in manual liquid-based cytology with hematoxylin and eosin staining. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2014, 85, 214-230.	1.5	78
168	From cancer screening to treatment: Service delivery and referral in the National Breast and Cervical Cancer Early Detection Program. <i>Cancer</i> , 2014, 120, 2549-2556.	4.1	44
169	2013 Statement on Human Papillomavirus DNA Test Utilization. <i>American Journal of Clinical Pathology</i> , 2014, 141, 459-461.	0.7	14
170	Genome-wide methylation profiling reveals Zinc finger protein 516 (ZNF516) and FK-506-binding protein 6 (FKBP6) promoters frequently methylated in cervical neoplasia, associated with HPV status and ethnicity in a Chilean population. <i>Epigenetics</i> , 2014, 9, 308-317.	2.7	28
171	Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. <i>BMJ, The</i> , 2014, 349, g5264-g5264.	6.0	133
172	Updated Guidelines for Cervical Cancer Screening. <i>Clinical Microbiology Newsletter</i> , 2014, 36, 95-103.	0.7	3
173	Validation of a Real-Time PCR-Based Qualitative Assay for the Detection of Methylated SEPT9 DNA in Human Plasma. <i>Clinical Chemistry</i> , 2014, 60, 1183-1191.	3.2	210
174	Role of cervical screening in older women. <i>Maturitas</i> , 2014, 79, 413-420.	2.4	21
175	Protecting the underscreened women in developed countries: the value of HPV test. <i>BMC Cancer</i> , 2014, 14, 574.	2.6	15
177	Evaluation of HPV GenoBlot Assay for screening and genotyping of human papillomavirus. <i>Biochip Journal</i> , 2014, 8, 60-66.	4.9	0
178	Examining and addressing evidence-practice gaps in cancer care: a systematic review. <i>Implementation Science</i> , 2014, 9, 37.	6.9	33
179	Teaching Moment: Why Promising Biomarkers Do Not Always Translate Into Clinically Useful Tests. <i>Journal of Clinical Oncology</i> , 2014, 32, 359-361.	1.6	12
180	Abnormal Cervical Cancer Screening in Pregnancy and Preterm Delivery. <i>Paediatric and Perinatal Epidemiology</i> , 2014, 28, 297-301.	1.7	15
181	Impact of the National Breast and Cervical Cancer Early Detection Program on Cervical Cancer Mortality Among Uninsured Low-Income Women in the U.S., 1991-2007. <i>American Journal of Preventive Medicine</i> , 2014, 47, 300-308.	3.0	25
182	2013 Statement on Human Papillomavirus DNA Test Utilization. <i>Journal of the American Society of Cytopathology</i> , 2014, 3, 87-89.	0.5	0
183	Cervical neoplasia-related factors and decreased prevalence of uterine fibroids among a cohort of African American women. <i>Fertility and Sterility</i> , 2014, 101, 208-214.	1.0	13
184	Human papillomavirus testing in patients with invasive cervical carcinoma: An institutional experience. <i>Journal of the American Society of Cytopathology</i> , 2014, 3, 126-130.	0.5	2
185	Spatial patterns of human papillomavirus-associated cancers within the state of Minnesota, 1998-2007. <i>Spatial and Spatio-temporal Epidemiology</i> , 2014, 9, 13-21.	1.7	6

#	ARTICLE	IF	CITATIONS
186	Filling a gap in cervical cancer screening programmes. <i>Lancet Oncology</i> , The, 2014, 15, 249-251.	10.7	18
187	Segmentation of cytoplasm and nuclei of abnormal cells in cervical cytology using global and local graph cuts. <i>Computerized Medical Imaging and Graphics</i> , 2014, 38, 369-380.	5.8	76
188	Liquid-based cytology and human papillomavirus testing: A pooled analysis using the data from 13 population-based cervical cancer screening studies from China. <i>Gynecologic Oncology</i> , 2014, 133, 172-179.	1.4	41
189	Delaying Pap Test Screening in the Adolescent Population: An Evidence-Based Approach. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2014, 27, 3-5.	0.7	8
190	Cervical Screening and Cervical Cancer Death Among Older Women: A Population-Based, Case-Control Study. <i>American Journal of Epidemiology</i> , 2014, 179, 1107-1114.	3.4	45
191	State of the Science: Cervical cancer screening in transition. <i>Gynecologic Oncology</i> , 2014, 133, 389-393.	1.4	9
193	Developing Guidelines for Cervical Cancer Prevention in the Face of Diagnostic Complexity. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 349-353.	4.9	5
194	Interobserver reproducibility and accuracy of p16/ <sc>K</sc> iâ€67 dualâ€stain cytology in cervical cancer screening. <i>Cancer Cytopathology</i> , 2014, 122, 914-920.	2.4	51
195	Understanding Factors Related to Women's Adherence to Colposcopy. <i>Nursing for Women's Health</i> , 2014, 18, 402-412.	0.8	5
197	Human papillomavirus prevalence and typeâ€distribution in cervical glandular neoplasias: Results from a <sc>E</sc>uropean multinational epidemiological study. <i>International Journal of Cancer</i> , 2015, 137, 2858-2868.	5.1	122
198	Cancer and lesbian, gay, bisexual, transgender/transsexual, and queer/questioning (LGBTQ) populations. <i>Ca-A Cancer Journal for Clinicians</i> , 2015, 65, 384-400.	329.8	361
199	Cervical Cancer Screening in Average-Risk Women: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. <i>Annals of Internal Medicine</i> , 2015, 162, 851-859.	3.9	54
200	Sexual Orientation Identity Disparities in Awareness and Initiation of the Human Papillomavirus Vaccine Among U.S. Women and Girls. <i>Annals of Internal Medicine</i> , 2015, 163, 99-106.	3.9	49
202	The Influence of Human Papillomavirus Genotypes on Visual Screening and Diagnosis of Cervical Precancer and Cancer. <i>Journal of Lower Genital Tract Disease</i> , 2015, 19, 220-223.	1.9	14
203	Primary cervical cancer screening. <i>CirurgÃa Y Cirujanos (English Edition)</i> , 2015, 83, 448-453.	0.0	1
205	Use of Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening. <i>Journal of Lower Genital Tract Disease</i> , 2015, 19, 91-96.	1.9	64
206	p16INK4a Immunohistochemical and Histopathologic Study of Pap Test Cases Interpreted as HSIL Without CIN2-3 Identification in Subsequent Cervical Specimens. <i>International Journal of Gynecological Pathology</i> , 2015, 34, 1.	1.4	2
207	Negative computerâ€maged ThinPrep Pap test and positive hybrid capture2 <sc>HPV</sc> coâ€testing results: A quality assurance review. <i>Diagnostic Cytopathology</i> , 2015, 43, 763-769.	1.0	4

#	ARTICLE	IF	CITATIONS
208	Prevalence of genital dysplasia after kidney transplantation – a retrospective, non-interventional study from two centers. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2015, 94, 891-897.	2.8	11
209	Comparison of clinical performances among Roche Cobas HPV, RFMP HPV PapilloTyper and Hybrid Capture 2 assays for detection of high-risk types of human papillomavirus. <i>Journal of Medical Virology</i> , 2015, 87, 1587-1593.	5.0	5
210	The Korean guideline for cervical cancer screening. <i>Journal of the Korean Medical Association</i> , 2015, 58, 398.	0.3	2
211	Issues in optimising and standardising the accuracy and utility of the colposcopic examination in the HPV era. <i>Ecancermedicalscience</i> , 2015, 9, 530.	1.1	17
212	Cervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choices. <i>World Journal of Clinical Oncology</i> , 2015, 6, 281.	2.3	185
213	Factors Affecting Gynecologic and Sexual Assessment in Older Women: A Lesson for Primary Care Providers. <i>Healthcare (Switzerland)</i> , 2015, 3, 683-694.	2.0	3
214	Current Cervical Carcinoma Screening Guidelines. <i>Journal of Clinical Medicine</i> , 2015, 4, 918-932.	2.4	30
215	Design of a Novel Low Cost Point of Care Tampon (POCkeT) Colposcope for Use in Resource Limited Settings. <i>PLoS ONE</i> , 2015, 10, e0135869.	2.5	55
216	The Korean guideline for cervical cancer screening. <i>Journal of Gynecologic Oncology</i> , 2015, 26, 232.	2.2	53
217	Three Doses to Finish: A Review on Completion of Human Papillomavirus (HPV) Vaccination among Adolescent Females Aged 12-17 years. , 2015, 05, .		0
218	Advances in Nanotechnology and Microfluidics for Human Papillomavirus Diagnostics. <i>Proceedings of the IEEE</i> , 2015, 103, 161-178.	21.3	32
219	Associations Between Provider Designation and Female-specific Cancer Screening in Women Veterans. <i>Medical Care</i> , 2015, 53, S47-S54.	2.4	27
220	Role of microRNAs in cancers of the female reproductive tract: insights from recent clinical and experimental discovery studies. <i>Clinical Science</i> , 2015, 128, 153-180.	4.3	12
221	Cobas 4800 HPV detection in the cervical, vaginal and urine samples of women with high-grade CIN before and after treatment. <i>Journal of Clinical Pathology</i> , 2015, 68, 567-570.	2.0	27
222	Reliability of the Xpert HPV Assay to Detect High-Risk Human Papillomavirus DNA in a Colposcopy Referral Population. <i>American Journal of Clinical Pathology</i> , 2015, 143, 126-133.	0.7	44
223	Cervical cancer screening in young and elderly women of the Xingu Indigenous Park: evaluation of the recommended screening age group in Brazil. <i>Einstein (Sao Paulo, Brazil)</i> , 2015, 13, 52-57.	0.7	6
224	Molecular cancer prevention: Current status and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2015, 65, 345-383.	329.8	83
225	The utility of high-risk HPV testing in the management of women 30 to 64 years of age with low-grade squamous intraepithelial lesions on cervical cytology. <i>Journal of the American Society of Cytopathology</i> , 2015, 4, 290-293.	0.5	0

#	ARTICLE	IF	CITATIONS
226	Oral cancer screening: serum Raman spectroscopic approach. <i>Journal of Biomedical Optics</i> , 2015, 20, 115006.	2.6	31
227	Risk of secondary solid malignancies after allogeneic hematopoietic stem cell transplantation and preventive strategies. <i>Future Oncology</i> , 2015, 11, 3175-3185.	2.4	22
228	The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology. <i>Journal of Clinical Virology</i> , 2015, 69, 52-55.	3.1	10
229	Avoiding cancer risk information. <i>Social Science and Medicine</i> , 2015, 147, 113-120.	3.8	101
230	A systematic review of p16/Ki-67 immunocytochemistry testing for triage of low grade cervical cytology. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2015, 122, 64-70.	2.3	32
231	Transitioning to a new era in cervical cancer screening. <i>Gynecologic Oncology</i> , 2015, 136, 175-177.	1.4	8
232	Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance. <i>Gynecologic Oncology</i> , 2015, 136, 178-182.	1.4	374
233	Urine-Based HPV Testing as a Method to Screen for Cervical Cancer. <i>Nursing for Women's Health</i> , 2015, 19, 59-65.	0.8	1
234	Cancer screening in the United States, 2015: A review of current American Cancer Society guidelines and current issues in cancer screening. <i>Ca-A Cancer Journal for Clinicians</i> , 2015, 65, 30-54.	329.8	299
235	Decreased Cancer Mortality-to-Incidence Ratios with Increased Accessibility of Federally Qualified Health Centers. <i>Journal of Community Health</i> , 2015, 40, 633-641.	3.8	37
236	Detection of Human Papillomavirus 16, 18, and 45 in Women With ASC-US Cytology and the Risk of Cervical Precancer. <i>American Journal of Clinical Pathology</i> , 2015, 143, 160-167.	0.7	32
237	Comparison of Human Papillomavirus Detection by Aptima HPV and cobas HPV Tests in a Population of Women Referred for Colposcopy following Detection of Atypical Squamous Cells of Undetermined Significance by Pap Cytology. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1277-1281.	3.9	39
238	Comparison of HybriBio GenoArray and Roche Human Papillomavirus (HPV) Linear Array for HPV Genotyping in Anal Swab Samples. <i>Journal of Clinical Microbiology</i> , 2015, 53, 550-556.	3.9	14
239	Robotic radical hysterectomy in early stage cervical cancer: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2015, 138, 457-471.	1.4	161
241	The significantly lower risk of cervical cancer at and after the recommended age to begin and end screening compared to breast and colorectal cancer. <i>Preventive Medicine</i> , 2015, 76, 135-140.	3.4	3
242	Acceptable and Preferred Cervical Cancer Screening Intervals Among U.S. Women. <i>American Journal of Preventive Medicine</i> , 2015, 49, e99-e107.	3.0	14
243	Cervical Cancer Screening Rates in a Chart Review of Adolescent Patients at an Academic Institution before and after the Publication of the 2009 American College of Obstetricians and Gynecologists' Recommendations. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2015, 28, 258-262.	0.7	7
244	Has recommended preventive service use increased after elimination of cost-sharing as part of the Affordable Care Act in the United States?. <i>Preventive Medicine</i> , 2015, 78, 85-91.	3.4	74

#	ARTICLE	IF	CITATIONS
245	A cornucopia of screening and diagnostic techniques for human papillomavirus associated cervical carcinomas. Journal of Virological Methods, 2015, 222, 192-201.	2.1	6
246	Perceived effectiveness of HPV test as a primary screening modality among US providers. Preventive Medicine, 2015, 78, 33-37.	3.4	11
247	Results of delayed triage by HPV testing and cytology in the Norwegian Cervical Cancer Screening Programme. Acta Oncologica, 2015, 54, 200-209.	1.8	10
248	A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results. Gynecologic Oncology, 2015, 138, 573-578.	1.4	49
249	<sc>HPV</sc>-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis. BJOG: an International Journal of Obstetrics and Gynaecology, 2015, 122, 119-127.	2.3	168
250	The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1304-1310.	2.5	44
251	Clinical Performance of Hybrid Capture 2 Human Papillomavirus Testing for Recurrent High-Grade Cervical/Vaginal Intraepithelial Neoplasm in Patients With an ASC-US Papanicolaou Test Result During Long-Term Posttherapy Follow-up Monitoring. Archives of Pathology and Laboratory Medicine, 2015, 139, 219-224.	2.5	5
252	Sociodemographic predictors of delayed- versus early-stage cervical cancer in California. Annals of Epidemiology, 2015, 25, 250-255.	1.9	22
253	El cribado del c�ncer de cuello de �tero en el Sistema P�blico de Salud de Catalu�a. Evaluaci�n y seguimiento durante el per�odo 2006-2012. Progresos En Obstetricia Y Ginecologia, 2015, 58, 209-220.	0.0	2
254	Health screening assistance â�� A patient centered approach. Geriatric Nursing, 2015, 36, 146-151.	1.9	0
255	Usefulness of vaginal cytology tests in women with previous hysterectomy for benign diseases: assessment of 53,891 tests. Gynecologic Oncology, 2015, 137, 270-273.	1.4	4
256	Provider management of equivocal cervical cancer screening results among underserved women, 2009��2011: follow-up of atypical squamous cells of undetermined significance. Cancer Causes and Control, 2015, 26, 759-764.	1.8	14
257	HPV-Type Distribution and Reproducibility of Histological Diagnosis in Cervical Neoplasia in Poland. Pathology and Oncology Research, 2015, 21, 703-711.	1.9	7
258	Plasma miR-127 and miR-218 Might Serve as Potential Biomarkers for Cervical Cancer. Reproductive Sciences, 2015, 22, 1037-1041.	2.5	25
259	Screening for Gynaecological Cancers. , 2015, , 267-281.		0
260	Identifying a â��Range of Reasonable Options��for Cervical Cancer Screening. Obstetrics and Gynecology, 2015, 125, 308-310.	2.4	12
261	Diagnostic performance of HPV E6/E7, hTERT, and Ki67 mRNA RT-qPCR assays on formalin-fixed paraffin-embedded cervical tissue specimens from women with cervical cancer. Experimental and Molecular Pathology, 2015, 98, 510-516.	2.1	16
262	New standard of care��HPV testing for cervical cancer screening. Nature Reviews Clinical Oncology, 2015, 12, 194-196.	27.6	6

#	ARTICLE	IF	CITATIONS
263	Guidelines on cervical and breast cancer screening in Greece. <i>Lancet, The</i> , 2015, 385, 772.	13.7	0
264	Accurate Segmentation of Cervical Cytoplasm and Nuclei Based on Multiscale Convolutional Network and Graph Partitioning. <i>IEEE Transactions on Biomedical Engineering</i> , 2015, 62, 2421-2433.	4.2	229
265	p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv257.	6.3	130
266	Cervical cancer screening among women ≥70 years of age in the United States—A referral problem or patient choice. <i>Preventive Medicine</i> , 2015, 81, 427-432.	3.4	12
267	Risk Assessment, Prevention, and Early Detection: Challenges for the Advanced Practice Nurse. <i>Seminars in Oncology Nursing</i> , 2015, 31, 306-326.	1.5	6
268	Squamous Cell Carcinoma of the Cervix: A Cytology-Histology-Human Papillomavirus Correlation in Clinical Practice. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 776-781.	2.5	10
269	Glandular Lesions of the Cervix in Clinical Practice: A Cytology, Histology, and Human Papillomavirus Correlation Study From 2 Institutions. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 1431-1436.	2.5	22
271	Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. <i>Cancer Cytopathology</i> , 2015, 123, 282-288.	2.4	123
272	Cervical Cancer Screening for Patients on the Female-to-Male Spectrum: a Narrative Review and Guide for Clinicians. <i>Journal of General Internal Medicine</i> , 2015, 30, 1857-1864.	2.6	116
273	Impact of Age and Comorbidity on Cervical and Breast Cancer Literacy of African Americans, Latina, and Arab Women. <i>Nursing Clinics of North America</i> , 2015, 50, 545-563.	1.5	9
274	Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: A systematic review and meta-analysis of randomised trials. <i>European Journal of Cancer</i> , 2015, 51, 2375-2385.	2.8	220
275	Cervical cancer screening (Pap testing) behaviours and acceptability of human papillomavirus self-testing among lesbian and bisexual women aged 21–26 years in the USA. <i>Journal of Family Planning and Reproductive Health Care</i> , 2015, 41, 259-264.	0.8	38
276	High prevalence of abnormal cervical smears in a hospital cohort of French women beyond the upper age limit screening program. <i>Preventive Medicine</i> , 2015, 81, 157-162.	3.4	2
277	Cytotoxic activity of acyl phloroglucinols isolated from the leaves of <i>Eucalyptus cinerea</i> F. Muell. ex Benth. cultivated in Egypt. <i>Scientific Reports</i> , 2014, 4, 5410.	3.3	27
278	Cost Effectiveness of Human Papillomavirus-16/18 Genotyping in Cervical Cancer Screening. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 95-107.	2.1	35
279	Human Papillomavirus Genotype-Specific Prevalence across the Continuum of Cervical Neoplasia and Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 230-240.	2.5	36
280	Multiple Biopsies and Detection of Cervical Cancer Precursors at Colposcopy. <i>Journal of Clinical Oncology</i> , 2015, 33, 83-89.	1.6	156
282	HPV and Cervical Dysplasia in Adolescents: A Progressive March Toward Prevention. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2015, 28, 127-131.	0.7	3

#	ARTICLE	IF	CITATIONS
283	Multimodal Entity Coreference for Cervical Dysplasia Diagnosis. IEEE Transactions on Medical Imaging, 2015, 34, 229-245.	8.9	61
284	Six1 overexpression at early stages of HPV16-mediated transformation of human keratinocytes promotes differentiation resistance and EMT. Virology, 2015, 474, 144-153.	2.4	15
285	Influences on human papillomavirus (HPV)-related information needs among women having HPV tests for follow-up of abnormal cervical cytology. Journal of Family Planning and Reproductive Health Care, 2015, 41, 134-141.	0.8	18
286	Human Papillomavirus. , 0, , 177-195.		1
287	Cervical Cancer in Human Immunodeficiency Virus (HIV) Positive Patients. , 0, , .		0
288	Developing a Smoking Cessation Intervention for Low Income and Minority Women. Journal of Women's Health Care, 2016, 05, .	0.2	7
289	Anal cancer and intraepithelial neoplasia screening: A review. World Journal of Gastrointestinal Surgery, 2016, 8, 41.	1.5	131
290	Prevalence characteristics of high-risk human papillomaviruses in women living in Shanghai with cervical precancerous lesions and cancer. Oncotarget, 2016, 7, 24656-24663.	1.8	22
291	Intimate Partner Violence and Barriers to Cervical Cancer Screening. Journal of Lower Genital Tract Disease, 2016, 20, 47-51.	1.9	17
292	Cervical Cancer Screening. Obstetrics and Gynecology, 2016, 127, 459-467.	2.4	21
293	Comparison of Three Different Commercial Kits for the Human Papilloma Virus Genotyping. Journal of Clinical Laboratory Analysis, 2016, 30, 1110-1115.	2.1	10
294	Discontent and Confusion: Primary Care Providers' Opinions and Understanding of Current Cervical Cancer Screening Recommendations. Journal of Women's Health, 2016, 25, 255-262.	3.3	26
295	Evaluation of Human Papillomavirus as a Risk Factor for Preterm Birth or Pregnancy-Related Hypertension. Obstetrics and Gynecology, 2016, 127, 233-240.	2.4	23
296	Clinical significance of atypical glandular cells in Pap tests: An analysis of more than 3000 cases at a large academic women's center. Cancer Cytopathology, 2016, 124, 589-595.	2.4	45
297	Comparison of Colposcopic Impression Based on Live Colposcopy and Evaluation of Static Digital Images. Journal of Lower Genital Tract Disease, 2016, 20, 154-161.	1.9	20
298	Direct comparison of two vaginal self-sampling devices for the detection of human papillomavirus infections. Journal of Clinical Virology, 2016, 82, 46-50.	3.1	41
299	Cervical Cancer Screening in the United Statesâ€“Affiliated Pacific Islands. Journal of Lower Genital Tract Disease, 2016, 20, 97-104.	1.9	4
300	Triage of <sc>ASCâ€“H</sc>: A metaâ€“analysis of the accuracy of highâ€“risk <sc>HPV</sc> testing and other markers to detect cervical precancer. Cancer Cytopathology, 2016, 124, 261-272.	2.4	25

#	ARTICLE	IF	CITATIONS
301	Can the careHPV test performed in mobile units replace cytology for screening in rural and remote areas?. Cancer Cytopathology, 2016, 124, 581-588.	2.4	17
302	US Navy Women's Experience of an Abnormal Cervical Cancer Screening. Journal of Midwifery and Women's Health, 2016, 61, 249-256.	1.3	8
303	Racial/Ethnic Differences Affecting Adherence to Cancer Screening Guidelines Among Women. Journal of Women's Health, 2016, 25, 371-380.	3.3	28
304	Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations. Obstetrics and Gynecology, 2016, 128, 1248-1257.	2.4	22
307	Centralized pap test diagnosis with artificial neural network and internet of things. , 2016, , .		2
308	Roles of Health Care Providers and Patients in Initiation of Unnecessary Papanicolaou Testing After Total Hysterectomy. American Journal of Public Health, 2016, 106, 2005-2011.	2.7	2
309	Gynecologic issues in the elderly. , 2016, , 398-407.		0
310	ACOG. Obstetrics and Gynecology, 2016, 128, e111-e130.	2.4	175
311	Preventive Care in Women's Health. Obstetrics and Gynecology Clinics of North America, 2016, 43, 165-180.	1.9	3
312	HPV Update: Vaccination, Screening, and Associated Disease. Journal of General Internal Medicine, 2016, 31, 1360-1366.	2.6	22
313	Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT framework. Journal of Clinical Virology, 2016, 81, 6-11.	3.1	25
314	Novel benchmark database of digitized and calibrated cervical cells for artificial intelligence based screening of cervical cancer. Journal of Ambient Intelligence and Humanized Computing, 2016, 7, 593-606.	4.9	13
315	Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS). Maturitas, 2016, 89, 63-72.	2.4	67
316	Human papillomavirus test with cytology triage in organized screening for cervical cancer. Acta Obstetrica Et Gynecologica Scandinavica, 2016, 95, 1220-1227.	2.8	17
317	Cervical Precancer and Cancer Risk by Human Papillomavirus Status and Cytologic Interpretation: Implications for Risk-Based Management. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1595-1599.	2.5	12
318	Molecular testing and cervical screening: will one test fit all?. Journal of the American Society of Cytopathology, 2016, 5, 331-338.	0.5	2
319	Accuracy of EasyChip HPV blot genotyping assay to detect high-risk HPV genotypes in SurePath Papanicolaou specimens. Journal of the American Society of Cytopathology, 2016, 5, 351-358.	0.5	0
320	Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement. Ca-A Cancer Journal for Clinicians, 2016, 66, 375-385.	329.8	60

#	ARTICLE	IF	CITATIONS
321	Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ system. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 408-436.	329.8	33
322	Population-Based Precision Cancer Screening: A Symposium on Evidence, Epidemiology, and Next Steps. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1449-1455.	2.5	43
323	Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 95-114.	329.8	198
324	Dietary flavonoid fisetin for cancer prevention and treatment. <i>Molecular Nutrition and Food Research</i> , 2016, 60, 1396-1405.	3.3	109
325	Management of high-risk HPV-positive women for detection of cervical (pre)cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 961-974.	3.1	45
326	Cervical cancer screening in women over 65. CON: Reasons for uncertainty. <i>Gynecologic Oncology</i> , 2016, 142, 383-384.	1.4	4
327	Full Breast Ultrasonography of Malignant Lesions. , 2016, , 211-287.		0
328	Follow up with <scp>HPV</scp> test and cytology as test of cure, 6Âmonths after conization, is reliable. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2016, 95, 1251-1257.	2.8	21
329	Human Papillomavirus. <i>Microbiology Spectrum</i> , 2016, 4, .	3.0	38
330	A Review of the Current Cervical Cancer Screening Guidelines. <i>North Carolina Medical Journal</i> , 2016, 77, 420-422.	0.2	6
331	A cohort study of cervical screening using partial HPV typing and cytology triage. <i>International Journal of Cancer</i> , 2016, 139, 2606-2615.	5.1	68
332	Triage of high-risk HPV positive women in cervical cancer screening. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1073-1085.	2.4	38
333	Effectiveness of four outreach modalities to patients overdue for cervical cancer screening in the primary care setting: a randomized trial. <i>Cancer Causes and Control</i> , 2016, 27, 1081-1091.	1.8	17
334	Cost-Effectiveness of Primary HPV Testing, Cytology and Co-testing as Cervical Cancer Screening for Women Above Age 30 Years. <i>Journal of General Internal Medicine</i> , 2016, 31, 1338-1344.	2.6	40
335	Disparities in Cervical Cancer Characteristics and Survival Between White Hispanics and White Non-Hispanic Women. <i>Journal of Women's Health</i> , 2016, 25, 1052-1058.	3.3	15
336	Sexual Orientation and Sexual and Reproductive Health among African American Sexual Minority Women in the U.S. South. <i>Women's Health Issues</i> , 2016, 26, 612-621.	2.0	18
337	Cervical cancer detection from MR images based on multiresolution wavelet analysis. , 2016, , .		0
338	Cervical cancer. <i>Nurse Practitioner</i> , 2016, 41, 18-23.	0.3	28

#	ARTICLE	IF	CITATIONS
339	Prevalence of Primary HPV in Djibouti: Feasibility of Screening for Early Diagnosis of Squamous Intraepithelial Lesions. <i>Journal of Lower Genital Tract Disease</i> , 2016, 20, 321-326.	1.9	4
340	Participation in cancer screening among female migrants and non-migrants in Germany. <i>Medicine (United States)</i> , 2016, 95, e4242.	1.0	17
341	Primary Care Physicians' Adherence to Expert Recommendations for Cervical Cancer Screening and Prevention in the Context of Human Papillomavirus Vaccination. <i>Sexually Transmitted Diseases</i> , 2016, 43, 438-444.	1.7	8
342	Reproducibility of cervical cytopathology following an intervention by an external quality control laboratory. <i>Diagnostic Cytopathology</i> , 2016, 44, 305-310.	1.0	4
343	Effect of number of human papillomavirus vaccine doses on guideline adherent cervical cytology screening among 19-26 year old females. <i>Preventive Medicine</i> , 2016, 88, 134-139.	3.4	10
344	Prevalence of High-Grade Intraepithelial Neoplasia in Patients with Cytology Presenting Atypical Squamous Cells of Undetermined Significance. <i>Acta Cytologica</i> , 2016, 60, 139-144.	1.3	2
345	Cell Block Preparation versus Liquid-Based Thin-Layer Cervical Cytology: A Comparative Study Evaluating Human Papillomavirus Testing by Hybrid Capture-2/Cervista, in situ Hybridization and p16 Immunohistochemistry. <i>Acta Cytologica</i> , 2016, 60, 145-153.	1.3	6
346	A risk-based framework to decide who benefits from screening. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 531-532.	27.6	11
347	Variation in Screening Abnormality Rates and Follow-Up of Breast, Cervical and Colorectal Cancer Screening within the PROSPR Consortium. <i>Journal of General Internal Medicine</i> , 2016, 31, 372-379.	2.6	34
348	Self-sampling HPV test in women not undergoing Pap smear for more than 5 years and factors associated with under-screening in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 1089-1096.	1.7	14
349	Use of claims data to estimate annual cervical cancer screening percentages in Portland metropolitan area, Oregon. <i>Cancer Epidemiology</i> , 2016, 41, 106-112.	1.9	2
350	Wilfully out of sight? A literature review on the effectiveness of cancer-related decision aids and implementation strategies. <i>BMC Medical Informatics and Decision Making</i> , 2016, 16, 36.	3.0	18
351	Perceptions of cervical cancer risk and screening among transmasculine individuals: patient and provider perspectives. <i>Culture, Health and Sexuality</i> , 2016, 18, 1192-1206.	1.8	50
352	Risk assessment to guide cervical screening strategies in a large Chinese population. <i>International Journal of Cancer</i> , 2016, 138, 2639-2647.	5.1	16
353	Pelvic Examination at the 6-Week Postpartum Visit After Cesarean Birth. <i>Journal of Midwifery and Women's Health</i> , 2016, 61, 497-500.	1.3	0
354	A Common Clinical Dilemma. <i>Journal of Lower Genital Tract Disease</i> , 2016, 20, 119-125.	1.9	11
355	Perception of Reproductive Health in Women with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 886-891.	1.3	46
356	Efficacy of reflex HPV16/18 genotyping in predicting CIN3/VAIN3 in women with HPV+/Pap- results. <i>Journal of the American Society of Cytopathology</i> , 2016, 5, 31-36.	0.5	4

#	ARTICLE	IF	CITATIONS
357	Triage of HPV positive women in cervical cancer screening. Journal of Clinical Virology, 2016, 76, S49-S55.	3.1	236
358	A randomized intervention study to evaluate whether electronic messaging can increase human papillomavirus vaccine completion and knowledge among college students. Journal of American College Health, 2016, 64, 269-278.	1.5	53
359	Using communication to manage uncertainty about cervical cancer screening guideline adherence among Appalachian women. Journal of Applied Communication Research, 2016, 44, 22-39.	1.2	16
360	Detection of high-risk human papillomavirus using menstrual blood in women with high-grade squamous intraepithelial lesions or high-risk human papillomavirus infections: A pilot study. Journal of Obstetrics and Gynaecology Research, 2016, 42, 319-324.	1.3	3
361	Why follow-back studies should be interpreted cautiously: The case of an HPV-negative cervical lesion. Cancer Cytopathology, 2016, 124, 66-67.	2.4	10
362	Cervical Cancer Screening Practices of Volunteer Providers in Faith-based Clinics. Journal for Nurse Practitioners, 2016, 12, 27-34.	0.8	1
363	Human Papillomavirus Laboratory Testing: the Changing Paradigm. Clinical Microbiology Reviews, 2016, 29, 291-319.	13.6	119
364	A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results. Gynecologic Oncology, 2016, 141, 364-370.	1.4	21
366	Improving the Rate of Colposcopy in an Urban Population of Patients With Known Abnormal Pap Smears. American Journal of Medical Quality, 2016, 31, 233-239.	0.5	0
368	Comparison of the performance of Anyplex II HPV HR, the Cobas 4800 human papillomavirus test and Hybrid Capture 2. Annals of Clinical Biochemistry, 2016, 53, 561-567.	1.6	15
369	Cervical screening program and the psychological impact of an abnormal Pap smear: a self-assessment questionnaire study of 590 patients. Archives of Gynecology and Obstetrics, 2016, 293, 391-398.	1.7	27
370	Claudin-1 as a Biomarker of Cervical Cytology and Histology. Pathology and Oncology Research, 2016, 22, 179-188.	1.9	14
371	VALGENT: A protocol for clinical validation of human papillomavirus assays. Journal of Clinical Virology, 2016, 76, S14-S21.	3.1	123
372	Salud es Vida: a Cervical Cancer Screening Intervention for Rural Latina Immigrant Women. Journal of Cancer Education, 2017, 32, 690-699.	1.3	33
373	Human papillomavirus molecular biology. Mutation Research - Reviews in Mutation Research, 2017, 772, 3-12.	5.5	146
374	Comparing Papanicolaou test results obtained during pregnancy and postpartum. Journal of Obstetrics and Gynaecology Research, 2017, 43, 705-709.	1.3	6
375	A 3-year interval is too short for re-screening women testing negative for human papillomavirus: a population-based cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2017, 124, 1585-1593.	2.3	16
376	Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention. Expert Review of Molecular Diagnostics, 2017, 17, 379-391.	3.1	55

#	ARTICLE	IF	CITATIONS
377	Hysterectomy in the Urologist's Practice. Current Urology Reports, 2017, 18, 4.	2.2	5
378	Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. Ca-A Cancer Journal for Clinicians, 2017, 67, 100-121.	329.8	529
379	Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm. Preventive Medicine, 2017, 98, 5-14.	3.4	87
380	Abnormal cervical cell detection based on an adaptive margin-based feature selection method. , 2017, , .		1
381	Gynecologists and human papillomavirus DNA testing: exploring knowledge, attitudes, and practice in Italy. European Journal of Cancer Prevention, 2017, 26, 249-256.	1.3	9
383	Cervical cancer screening intervals and management for women living with HIV. Aids, 2017, 31, 1035-1044.	2.2	22
384	Cervical Cancer Screening and Incidence by Age: Unmet Needs Near and After the Stopping Age for Screening. American Journal of Preventive Medicine, 2017, 53, 392-395.	3.0	46
385	Correlates of Human Papillomavirus Infection Among a National Sample of Sexual Minority Women. Journal of Women's Health, 2017, 26, 1004-1011.	3.3	12
386	Cervical Cancer Screening. Medical Clinics of North America, 2017, 101, 743-753.	2.5	24
387	Primary HPV testing verification: A retrospective ad hoc analysis of screening algorithms on women doubly tested for cytology and HPV. Diagnostic Cytopathology, 2017, 45, 580-586.	1.0	9
388	When Less is More. Journal of the National Cancer Institute, 2017, 109, djw240.	6.3	1
389	DeepPap: Deep Convolutional Networks for Cervical Cell Classification. IEEE Journal of Biomedical and Health Informatics, 2017, 21, 1633-1643.	6.3	317
390	Preparing for the Next Round of ASCCP-Sponsored Cervical Screening and Management Guidelines. Journal of Lower Genital Tract Disease, 2017, 21, 87-90.	1.9	23
391	Comparison of the cervista HPV HR test and luminex XMAP technology for the diagnosis of cervical intraepithelial neoplasia. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 214, 150-155.	1.1	5
392	Clinical progress of human papillomavirus genotypes and their persistent infection in subjects with atypical squamous cells of undetermined significance cytology: Statistical and latent Dirichlet allocation analysis. Experimental and Therapeutic Medicine, 2017, 13, 3032-3038.	1.8	3
393	Prevalence characteristics of cervical human papillomavirus (HPV) genotypes in the Taizhou area, China: a cross-sectional study of 37,967 women from the general population. BMJ Open, 2017, 7, e014135.	1.9	27
394	Awareness of Cervical Cancer Causes and Predeterminants of Likelihood to Screen Among Women in Haiti. Journal of Lower Genital Tract Disease, 2017, 21, 37-41.	1.9	10
395	Cervical Cancer: Prevention and Early Detection. Seminars in Oncology Nursing, 2017, 33, 172-183.	1.5	151

#	ARTICLE	IF	CITATIONS
396	Carcinogenicity of Human Papillomavirus (HPV) Types in HIV-Positive Women: A Meta-Analysis From HPV Infection to Cervical Cancer. <i>Clinical Infectious Diseases</i> , 2017, 64, 1228-1235.	5.8	124
397	Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women. <i>Modern Pathology</i> , 2017, 30, 1021-1031.	5.5	49
398	Laparoscopic Radical Hysterectomy in Early Stage Cervical Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2017, 27, 1132-1144.	1.0	50
399	Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice. <i>International Journal of Cancer</i> , 2017, 140, 2192-2200.	5.1	83
400	Understanding women's hesitancy to undergo less frequent cervical cancer screening. <i>Preventive Medicine</i> , 2017, 95, 96-102.	3.4	27
401	Development and Validation of a Preanalytic Procedure for Performing the cobas HPV Test in SurePath Preservative Fluid. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 288-294.	2.8	5
402	Sexual orientation and sexual health services utilization among women in the United States. <i>Preventive Medicine</i> , 2017, 95, 74-81.	3.4	54
403	Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. <i>European Journal of Cancer</i> , 2017, 86, 305-317.	2.8	22
404	Preventive Health for Transgender Men and Women. <i>Seminars in Reproductive Medicine</i> , 2017, 35, 426-433.	1.1	9
405	Human Papillomavirus-Related Cancer Surveillance, Prevention, and Screening Among Transgender Men and Women: Neglected Populations at High Risk. <i>LGBT Health</i> , 2017, 4, 315-319.	3.4	40
406	Diagnosis and Management of Noncardiac Complications in Adults With Congenital Heart Disease: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2017, 136, e348-e392.	1.6	147
407	ASCCP Colposcopy Standards: Risk-Based Colposcopy Practice. <i>Journal of Lower Genital Tract Disease</i> , 2017, 21, 230-234.	1.9	56
408	Amplification of specific chromosomal regions assessed by fluorescent in situ hybridization on Pap smears to be added as screening tool for identifying women at risk of progressing to cervical cancer. <i>Tumor Biology</i> , 2017, 39, 101042831769836.	1.8	3
409	Primary HPV testing recommendations of US providers, 2015. <i>Preventive Medicine</i> , 2017, 105, 372-377.	3.4	13
410	Effective use of human papillomavirus testing for cervical cancer screening requires extended intervals to target persistent infections and precancerous lesions. <i>Preventive Medicine</i> , 2017, 105, 378-380.	3.4	3
411	Declining prevalence of cytological squamous intraepithelial lesions of the cervix among women living with well-controlled HIV – “Most women living with HIV do not need annual PAP smear screening. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2017, 96, 1330-1337.	2.8	8
412	Can Promote an Existential Crisis? Factors Influencing Pap Test Acceptability and Utilization Among Transmasculine Individuals. <i>Qualitative Health Research</i> , 2017, 27, 2138-2149.	2.1	64
413	Human Papillomavirus Vaccination and Pap Smear Uptake Among Young Women in the United States: Role of Provider and Patient. <i>Journal of Women's Health</i> , 2017, 26, 1114-1122.	3.3	11

#	ARTICLE	IF	CITATIONS
414	Defining Optimal Triage Strategies for hrHPV Screenâ€‘Positive Womenâ€‘An Evaluation of HPV 16/18 Genotyping, Cytology, and p16/Ki-67 Cytoimmunochemistry. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1629-1635.	2.5	36
416	The ATHENA HPV study underrepresents â€‘otherâ€‘high-risk HPV genotypes when compared with a diverse New York City population. Cytopathology, 2017, 28, 413-418.	0.7	5
417	Stratifying HPVâ€‘positive women for CIN3+ risk after one and two rounds of HPVâ€‘based screening. International Journal of Cancer, 2017, 141, 1551-1560.	5.1	7
419	Impact of a student-led community education program to promote Pap test screening among Asian-American women. Journal of the American Society of Cytopathology, 2017, 6, 145-154.	0.5	5
420	Detection of cervical precancerous lesions with Aptima HPV assays using SurePath preservative fluid specimens. Papillomavirus Research (Amsterdam, Netherlands), 2017, 3, 155-159.	4.5	3
421	A three miRNAs signature predicts survival in cervical cancer using bioinformatics analysis. Scientific Reports, 2017, 7, 5624.	3.3	60
422	The Affordable Care Act and Cancer Care for Young Adults. Cancer Journal (Sudbury, Mass), 2017, 23, 194-198.	2.0	12
423	Discrepant HPV/cytology cotesting results: Are there differences between cytologyâ€‘negative versus HPVâ€‘negative cervical intraepithelial neoplasia?. Cancer Cytopathology, 2017, 125, 795-805.	2.4	7
424	Women's understanding of their Pap and HPV test results: Implications for patientâ€‘provider communication. Journal of Communication in Healthcare, 2017, 10, 37-46.	1.5	8
425	Regional and Socioeconomic Differences in the Coverage of the Papanicolaou Test in Brazil: Data from the Brazilian Health Survey 2013. Revista Brasileira De Ginecologia E Obstetricia, 2017, 39, 480-487.	0.8	13
426	Outcomes in Women With Cytology Showing Atypical Squamous Cells of Undetermined Significance With vs Without Human Papillomavirus Testing. JAMA Oncology, 2017, 3, 1327.	7.1	13
427	Navigating the cervical cancer screening guidelines for women aged older than 65 years. Menopause, 2017, 24, 1302-1303.	2.0	3
428	Cervical Cancer Screening and Prevention in 78 Sexually Transmitted Disease Clinicsâ€‘United States, 2014â€‘2015. Sexually Transmitted Diseases, 2017, 44, 637-641.	1.7	4
429	Why does cervical cancer occur in a state-of-the-art screening program?. Gynecologic Oncology, 2017, 146, 546-553.	1.4	47
430	Effects of peer health education on perception and practice of screening for cervical cancer among urban residential women in south-east Nigeria: a before and after study. BMC Women's Health, 2017, 17, 41.	2.0	47
431	Differences in age-specific HPV prevalence between self-collected and health personnel collected specimen in a cross-sectional study in Ghana. Infectious Agents and Cancer, 2017, 12, 26.	2.6	4
434	Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline. Journal of Global Oncology, 2017, 3, 635-657.	0.5	121
435	Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus. Journal of the National Cancer Institute, 2017, 109, djw216.	6.3	72

#	ARTICLE	IF	CITATIONS
436	Health Service Accessibility and Risk in Cervical Cancer Prevention: Comparing Rural Versus Nonrural Residence in New Mexico. <i>Journal of Rural Health</i> , 2017, 33, 382-392.	2.9	25
437	Accurate Cervical Cell Segmentation from Overlapping Clumps in Pap Smear Images. <i>IEEE Transactions on Medical Imaging</i> , 2017, 36, 288-300.	8.9	167
438	Human Papillomavirus Infections. , 2017, , 575-584.e1.		0
439	Harms of cervical cancer screening in the United States and the Netherlands. <i>International Journal of Cancer</i> , 2017, 140, 1215-1222.	5.1	46
440	Human Papillomavirus and Its Testing Assays, Cervical Cancer Screening, and Vaccination. <i>Advances in Clinical Chemistry</i> , 2017, 81, 135-192.	3.7	13
441	Attitude to Human Papillomavirus Deoxyribonucleic Acid-Based Cervical Cancer Screening in Antenatal Care in Nigeria: A Qualitative Study. <i>Frontiers in Public Health</i> , 2017, 5, 226.	2.7	9
442	Virus/Host Cell Crosstalk in Hypoxic HPV-Positive Cancer Cells. <i>Viruses</i> , 2017, 9, 174.	3.3	9
443	Nationwide cervical cancer screening in Korea: data from the National Health Insurance Service Cancer Screening Program and National Cancer Screening Program, 2009â€“2014. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e63.	2.2	19
444	Recent trends in racial and regional disparities in cervical cancer incidence and mortality in United States. <i>PLoS ONE</i> , 2017, 12, e0172548.	2.5	117
445	Detection assay for HPV16 and HPV18 by loop-mediated isothermal amplification with lateral flow dipstick tests. <i>Molecular Medicine Reports</i> , 2017, 15, 3203-3209.	2.4	16
446	Development of quality indicators for non-small cell lung cancer care: a first step toward assessing and improving quality of cancer care in China. <i>BMC Cancer</i> , 2017, 17, 603.	2.6	12
447	Comparison of human papillomavirus (HPV) detection in urine and cervical swab samples using the HPV GenoArray Diagnostic assay. <i>PeerJ</i> , 2017, 5, e3910.	2.0	16
448	Women with inflammatory bowel diseases have a suboptimal cervical cancer screening rate and are not aware of the recommended human papilloma virus vaccine. <i>Gynecological Endocrinology</i> , 2018, 34, 656-658.	1.7	7
449	Trends in Cervical Cancer Screening in California's Family Planning Program. <i>Journal of Lower Genital Tract Disease</i> , 2018, 22, 171-177.	1.9	3
450	Anticipating the Impact of Human Papillomavirus Vaccination on US Cervical Cancer Prevention Strategies. <i>Journal of Lower Genital Tract Disease</i> , 2018, 22, 123-125.	1.9	1
451	Liquid-based cytology versus conventional cytology for detection of uterine cervical lesions: a prospective observational study. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 522-528.	1.3	12
452	Influence of age on histologic outcome of cervical intraepithelial neoplasia during observational management: results from large cohort, systematic review, meta-analysis. <i>Scientific Reports</i> , 2018, 8, 6383.	3.3	46
453	The Onclarity Human Papillomavirus Trial: Design, methods, and baseline results. <i>Gynecologic Oncology</i> , 2018, 149, 498-505.	1.4	51

#	ARTICLE	IF	CITATIONS
454	Timely follow-up of positive cancer screening results: A systematic review and recommendations from the <sc>PROSPR</sc> Consortium. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 199-216.	329.8	63
457	The clinical value of HPV E6/E7 and STAT3 mRNA detection in cervical cancer screening. <i>Pathology Research and Practice</i> , 2018, 214, 767-775.	2.3	14
458	Human Papillomaviruses. , 2018, , 1101-1105.e1.		0
459	Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening. <i>Journal of the National Cancer Institute</i> , 2018, 110, 501-508.	6.3	116
460	Improving the Accuracy of a Clinical Decision Support System for Cervical Cancer Screening and Surveillance. <i>Applied Clinical Informatics</i> , 2018, 09, 062-071.	1.7	9
461	Primary HPV cervical cancer screening in the United States: Are we ready?. <i>Journal of the American Society of Cytopathology</i> , 2018, 7, 50-55.	0.5	12
462	Cervical Cancer Screening Experiences Among Chinese American Immigrant Women in the United States. <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 2018, 47, 52-63.	0.5	14
463	Primary HPV testing: U.S. women's awareness and acceptance of an emerging screening modality. <i>Preventive Medicine</i> , 2018, 108, 111-114.	3.4	12
464	Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting. <i>Preventive Medicine</i> , 2018, 109, 44-50.	3.4	14
465	HPV genotype determination and E6/E7 mRNA detection for management of HPV positive women. <i>Virology Journal</i> , 2018, 15, 52.	3.4	25
466	Racial/Ethnic Disparities in Cervical Cancer Screening Services Among Contractors of the Connecticut Breast and Cervical Cancer Early Detection Program. <i>Health Equity</i> , 2018, 2, 30-36.	1.9	18
467	The association between cervical inflammation and histologic evidence of HPV in PAP smears and adverse pregnancy outcome in low risk population. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 225, 160-165.	1.1	17
468	Ending Cervical Cancer Screening in Low-Risk Women After Age 65. <i>Health Services Research and Managerial Epidemiology</i> , 2018, 5, 233339281875524.	0.9	2
469	The Next Generation of Cervical Cancer Screening: Should Guidelines Focus on Best Practices for the Future or Current Screening Capacity?. <i>Journal of Lower Genital Tract Disease</i> , 2018, 22, 91-96.	1.9	8
470	Increased Rate of ASCUS Diagnosis With Concomitant Request for High-Risk Human Papillomavirus Reflex Testing May Be Due to Cognitive Bias. <i>American Journal of Clinical Pathology</i> , 2018, 149, 425-433.	0.7	1
471	Cervical screening in HPV-vaccinated populations. <i>Climacteric</i> , 2018, 21, 227-234.	2.4	8
472	A prospective study of risk-based colposcopy demonstrates improved detection of cervicalÂprecancers. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 604.e1-604.e8.	1.3	23
473	Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S.. <i>Preventive Medicine</i> , 2018, 111, 177-179.	3.4	7

#	ARTICLE	IF	CITATIONS
474	Cervical Cancer Screening and Its Associated Factors Among North Korean Defectors Living in South Korea. <i>Journal of Immigrant and Minority Health</i> , 2018, 20, 66-72.	1.6	2
475	Effects of an Education Intervention about HPV Self-Testing for Healthcare Providers and Staff. <i>Journal of Cancer Education</i> , 2018, 33, 954-959.	1.3	8
476	Multi-cell nuclei segmentation in cervical cancer images by integrated feature vectors. <i>Multimedia Tools and Applications</i> , 2018, 77, 9271-9290.	3.9	19
477	Increasing Breast and Cervical Cancer Screening in Rural and Border Texas with Friend to Friend Plus Patient Navigation. <i>Journal of Cancer Education</i> , 2018, 33, 798-805.	1.3	17
478	Cytology and high risk <sc>HPV</sc> testing in cervical cancer screening program: Outcome of 3â€‘year followâ€‘up in an academic institute. <i>Diagnostic Cytopathology</i> , 2018, 46, 22-27.	1.0	6
479	The clinical performance of computerâ€‘assisted liquidâ€‘based cytology, primary hrHPV screening, and cotesting at a Turkish Tertiary Care Hospital. <i>Diagnostic Cytopathology</i> , 2018, 46, 3-8.	1.0	2
480	What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study. <i>International Journal of Cancer</i> , 2018, 142, 709-718.	5.1	45
481	Risks factors and timing of genital human papillomavirus (HPV) infection in female stem cell transplant survivors: a longitudinal study. <i>Bone Marrow Transplantation</i> , 2018, 53, 78-83.	2.4	26
482	The natural history of human papillomavirus infection. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2018, 47, 2-13.	2.8	280
483	Human Papillomavirus Testing by Veterans Administration Women's Health Providers: Are They Adhering to Guidelines?. <i>Journal of Women's Health</i> , 2018, 27, 179-182.	3.3	2
484	Sexually Transmitted Diseases in Adolescence. , 2018, , 211-238.		1
485	Can Human Papillomavirus DNA Self-sampling be an Acceptable and Reliable Option for Cervical Cancer Screening in Female Sex Workers?. <i>Cancer Nursing</i> , 2018, 41, 45-52.	1.5	9
486	Uterine Cervical Cancer Screening. , 2018, , .		0
487	Secondary Prevention of Uterine Cervical Cancer. , 2018, , .		2
488	Non-PCR Amplification Techniques. , 2018, , 347-375.		0
489	Evolving role of pharmaceutical physicians in medical evidence and education. <i>Advances in Medical Education and Practice</i> , 2018, Volume 9, 777-790.	1.5	19
490	Nucleus Region Segmentation Towards Cervical Cancer Screening Using AGMC-TU Pap-Smear Dataset. , 2018, , .		5
491	Clinical validation of the Cervista<sup>g&t®</sup>®<sup>g&t®</sup> high-risk human papillomavirus test in Chinese women from Fujian province: a cross-sectional study. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 2243-2253.	2.0	2

#	ARTICLE	IF	CITATIONS
492	A Study on Cervical Cancer Screening Using Pap Smear Test and Clinical Correlation. Asia-Pacific Journal of Oncology Nursing, 2018, 5, 337-341.	1.6	66
493	Variations in Progression and Regression of Precancerous Lesions of the Uterine Cervix on Cytology Testing Among Women of Different Races. Journal of Osteopathic Medicine, 2018, 118, 8-18.	0.8	3
494	An advocacy victory: final USPSTF cervical cancer screening recommendations revised to include cotesting option. Journal of the American Society of Cytopathology, 2018, 7, 333-335.	0.5	7
495	Automatic Segmentation of Cervical Nuclei Based on Deep Learning and a Conditional Random Field. IEEE Access, 2018, 6, 53709-53721.	4.2	54
496	Evaluation of Sensitivity and Specificity of Pap Smear, LBC and HPV in Screening of Cervical Cancer. Indian Journal of Gynecologic Oncology, 2018, 16, 1.	0.3	9
497	Molecular Microbiology. , 2018, , 87-124.		0
499	Survey of Cervical Cancer Prediction Using Machine Learning: A Comparative Approach. , 2018, , .		12
500	Nuclear lactate dehydrogenase A senses ROS to produce γ -hydroxybutyrate for HPV-induced cervical tumor growth. Nature Communications, 2018, 9, 4429.	12.8	115
501	HPV genotyping and E6/E7 transcript assays for cervical lesion detection in an Asian screening populationâ€”Cobas and Aptima HPV tests. Journal of Clinical Virology, 2018, 109, 13-18.	3.1	4
502	Whose cervical screening model predictions will prove to be correct?. Journal of the American Society of Cytopathology, 2018, 7, 289-291.	0.5	2
503	Reducing overuse of cervical cancer screening: A systematic review. Preventive Medicine, 2018, 116, 51-59.	3.4	18
504	Awareness, Positivity of Pap Smear in Adult Females. Indian Journal of Gynecologic Oncology, 2018, 16, 1.	0.3	2
505	Has the Time Come to Discontinue Routine Pelvic Examination?. Journal of Midwifery and Women's Health, 2018, 63, 513-515.	1.3	1
506	Deep learning for image-based cancer detection and diagnosisâ€”A survey. Pattern Recognition, 2018, 83, 134-149.	8.1	353
507	Cervical Cancer Incidence in Young U.S. Females After Human Papillomavirus Vaccine Introduction. American Journal of Preventive Medicine, 2018, 55, 197-204.	3.0	109
508	Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. Ca-A Cancer Journal for Clinicians, 2018, 68, 297-316.	329.8	433
509	A Retrospective Study of Cytology, High-Risk HPV, and Colposcopy Results of Vaginal Intraepithelial Neoplasia Patients. BioMed Research International, 2018, 2018, 1-6.	1.9	17
510	Portable Pocket colposcopy performs comparably to standardâ€”care clinical colposcopy using acetic acid and Lugol's iodine as contrast mediators: an investigational study in Peru. BJOG: an International Journal of Obstetrics and Gynaecology, 2018, 125, 1321-1329.	2.3	25

#	ARTICLE	IF	CITATIONS
511	Factors affecting Pap smear uptake in a maternity hospital: A descriptive cross-sectional study. Journal of Advanced Nursing, 2018, 74, 2533-2543.	3.3	6
512	Bispecific affibody molecule targeting HPV16 and HPV18E7 oncoproteins for enhanced molecular imaging of cervical cancer. Applied Microbiology and Biotechnology, 2018, 102, 7429-7439.	3.6	16
513	Methylation of the hsa-miR-124, SOX1, TERT, and LMX1A genes as biomarkers for precursor lesions in cervical cancer. Gynecologic Oncology, 2018, 150, 545-551.	1.4	44
514	Educational Case: Cervical Neoplasia. Academic Pathology, 2018, 5, 2374289518770651.	1.1	0
515	How confident can we be in the current guidelines for exiting cervical screening?. Preventive Medicine, 2018, 114, 188-192.	3.4	27
516	Cervical Cancer Screening Intervals Preferred by U.S. Women. American Journal of Preventive Medicine, 2018, 55, 389-394.	3.0	13
517	Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions. BMC Cancer, 2018, 18, 112.	2.6	43
518	MicroRNA expression in cervical cancer: Novel diagnostic and prognostic biomarkers. Journal of Cellular Biochemistry, 2018, 119, 7080-7090.	2.6	82
519	Novel cytomorphologic characteristics suggesting human papillomavirus infection in patients diagnosed as negative for intraepithelial lesion or malignancy and a comparison of diagnostic performance of three human papillomavirus tests. Diagnostic Cytopathology, 2018, 46, 833-839.	1.0	2
520	Changing practice patterns for cytotechnologists: a comparative analysis of data from the 2009 and 2015 ASCP BOC Practice Analysis Surveys. Journal of the American Society of Cytopathology, 2018, 7, 232-239.	0.5	5
521	Comparison of cervical cancer screening among women with and without hysterectomies: a nationwide population-based study in Korea. BMC Cancer, 2018, 18, 810.	2.6	3
523	Update on primary HPV screening for cervical cancer prevention. Current Problems in Cancer, 2018, 42, 507-520.	2.0	22
524	Changing Practice Patterns for Cytotechnologists: A Comparative Analysis of Data from the 2009 and 2015 ASCP BOC Practice Analysis Surveys. Laboratory Medicine, 2018, 49, 195-202.	1.2	3
525	Enhanced Detection of Cervical Cancer and Precancer Through Use of Imaged Liquid-Based Cytology in Routine Cytology and HPV Cotesting. American Journal of Clinical Pathology, 2018, 150, 385-392.	0.7	33
526	Screening for Cervical Cancer in Primary Care. JAMA - Journal of the American Medical Association, 2018, 320, 706.	7.4	112
527	Cervical Cancer Screening—Moving From the Value of Evidence to the Evidence of Value. JAMA Internal Medicine, 2018, 178, 1293.	5.1	4
528	Cervical cancer in women over 65: An analysis of screening. Gynecologic Oncology Reports, 2018, 25, 48-51.	0.6	23
529	Correlates of Cervical Cancer Screening Adherence Among Women in the U.S.: Findings from HINTS 2013–2014. Journal of Primary Prevention, 2018, 39, 329-344.	1.6	17

#	ARTICLE	IF	CITATIONS
530	A prospective pilot evaluation of vaginal and urine self-sampling for the Roche cobas 4800 HPV test for cervical cancer screening. Scientific Reports, 2018, 8, 9015.	3.3	21
531	Test performance and acceptability of self- versus provider-collected swabs for high-risk HPV DNA testing in female-to-male trans masculine patients. PLoS ONE, 2018, 13, e0190172.	2.5	83
532	Cervical cancer screening among HIV-infected women in an urban, United States safety-net healthcare system. Aids, 2018, 32, 1861-1870.	2.2	11
533	Optimal <i>M</i>-Switch Surveillance Policies for Liver Cancer in a Hepatitis Câ€“Infected Population. Operations Research, 2018, 66, 673-696.	1.9	18
534	Perspectives on cervical cancer screening and prevention: challenges faced by providers and patients along the Texasâ€“Mexico border. Perspectives in Public Health, 2019, 139, 199-205.	1.6	24
536	Characteristics of women infected with human papillomavirus in a tertiary hospital in Beijing China, 2014â€“2018. BMC Infectious Diseases, 2019, 19, 670.	2.9	24
537	Human papillomavirus (HPV) DNA and mRNA primary cervical cancer screening: Evaluation and triaging options for HPV-positive women. Journal of Medical Screening, 2019, 26, 212-218.	2.3	1
538	Cancer Screening in Women. Obstetrics and Gynecology Clinics of North America, 2019, 46, 485-499.	1.9	13
539	Risk of cervical and vaginal dysplasia after surgery for vulvar intraepithelial neoplasia or cancer: A 6â€“year follow-up study. Gynecologic Oncology, 2019, 155, 88-92.	1.4	10
540	HPV16-transformed human keratinocytes depend on SIX1 expression for proliferation and HPV E6/E7 gene expression. Virology, 2019, 537, 20-30.	2.4	4
542	Assessment of the current state of knowledge and risk factors of cervical cancer among women in the Buea Health District, Cameroon. Pan African Medical Journal, 2019, 33, 38.	0.8	13
543	Acceptability of Human Papillomavirus Self-Sampling Among a National Sample of Women in the United States. BioResearch Open Access, 2019, 8, 65-73.	2.6	20
544	Clinical Evaluation of Atypical Glandular Cells Detected on Cervical Cytological Examination in a Tertiary Hospital. Indian Journal of Gynecologic Oncology, 2019, 17, 1.	0.3	0
545	Curcumin inhibits NF-kB and Wnt/Î²-catenin pathways in cervical cancer cells. Pathology Research and Practice, 2019, 215, 152556.	2.3	190
546	How Do Older Adults Consider Age, Life Expectancy, Quality of Life, and Physician Recommendations When Making Cancer Screening Decisions? Results from a National Survey Using a Discrete Choice Experiment. Medical Decision Making, 2019, 39, 621-631.	2.4	11
547	Segmentation of Overlapping Cytoplasm in Cervical Smear Images via Adaptive Shape Priors Extracted From Contour Fragments. IEEE Transactions on Medical Imaging, 2019, 38, 2849-2862.	8.9	17
548	Gynecologic Cytology. , 2019, , 571-630.		1
549	Prevention of chronic diseases in middle-age women: a cross-sectional study on an Italian large sample. European Journal of Public Health, 2019, 30, 70-75.	0.3	1

#	ARTICLE	IF	CITATIONS
550	High-risk human papilloma virus infection and cervical neoplasm in female inflammatory bowel disease patients: a cross-sectional study. <i>Gastroenterology Report</i> , 2019, 7, 338-344.	1.3	19
551	Advances in Precision Health and Emerging Diagnostics for Women. <i>Journal of Clinical Medicine</i> , 2019, 8, 1525.	2.4	6
552	JOint Shape Matching for Overlapping Cytoplasm Segmentation in Cervical Smear Images. , 2019, , .		2
553	Combined dynamic spectral imaging and routine colposcopy strategy for the diagnosis of preâ€cancerous cervical lesions. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 1521-1526.	1.8	0
554	Profile of women with anal neoplasia associated with cervical neoplasia receiving care at a tertiary healthcare facility in northeastern Brazil. <i>Journal of Coloproctology</i> , 2019, 39, 297-302.	0.1	0
555	Exploring an Appropriate Method of Cervical Cancer Screening in Rural China. <i>Asia-Pacific Journal of Public Health</i> , 2019, 31, 652-658.	1.0	3
556	Classification of Colposcopic Cervigrams Using EMD in R. <i>Communications in Computer and Information Science</i> , 2019, , 298-308.	0.5	4
557	Pathology and Molecular Diagnosis of Cervical Cancer and Precursor Lesions. , 2019, , 61-87.		0
558	Maternal Human Papillomavirus and Preterm Premature Rupture of Membranes: A Retrospective Cohort Study. <i>Journal of Women's Health</i> , 2019, 28, 606-611.	3.3	12
559	Cancer Screening and Prevention Highlights in Gynecologic Cancer. <i>Obstetrics and Gynecology Clinics of North America</i> , 2019, 46, 19-36.	1.9	11
560	Fine-Grained Classification of Cervical Cells Using Morphological and Appearance Based Convolutional Neural Networks. <i>IEEE Access</i> , 2019, 7, 71541-71549.	4.2	74
561	Cervical cancer in the Bamenda Regional Hospital, North West Region of Cameroon: a retrospective study. <i>Pan African Medical Journal</i> , 2019, 32, 90.	0.8	10
562	Cervical Cancer Screening. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2018.	7.4	108
563	Transmasculine Hormone Therapy. <i>Endocrinology and Metabolism Clinics of North America</i> , 2019, 48, 357-375.	3.2	12
564	Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis. <i>BMJ Global Health</i> , 2019, 4, e001351.	4.7	158
565	Prevalence of abnormal cervical cancer screening outcomes among screening-compliant women in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 75-77.	1.3	3
566	Human papillomavirus infection in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clinical Transplantation</i> , 2019, 33, e13590.	1.6	66
567	Estimated Quality of Life and Economic Outcomes Associated With 12 Cervical Cancer Screening Strategies. <i>JAMA Internal Medicine</i> , 2019, 179, 867.	5.1	28

#	ARTICLE	IF	CITATIONS
568	Bethesda 2014 Implementation and Human Papillomavirus Primary Screening: Practices of Laboratories Participating in the College of American Pathologists PAP Education Program. Archives of Pathology and Laboratory Medicine, 2019, 143, 1196-1202.	2.5	20
569	Cancer screening: health impact, prevalence, correlates, and interventions. Psychology and Health, 2019, 34, 1036-1072.	2.2	20
570	Computer-Aided Diagnosis of Label-Free 3-D Optical Coherence Microscopy Images of Human Cervical Tissue. IEEE Transactions on Biomedical Engineering, 2019, 66, 2447-2456.	4.2	28
571	PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort. Journal of Gynecologic Oncology, 2019, 30, e29.	2.2	10
572	Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. Ca-A Cancer Journal for Clinicians, 2019, 69, 184-210.	329.8	448
573	The Epidemiology of Cancer Among Homeless Adults in Metropolitan Detroit. JNCI Cancer Spectrum, 2019, 3, pkz006.	2.9	18
574	Binary tree-like network with two-path Fusion Attention Feature for cervical cell nucleus segmentation. Computers in Biology and Medicine, 2019, 108, 223-233.	7.0	19
575	Current Prevalence of Major Cancer Risk Factors and Screening Test Use in the United States: Disparities by Education and Race/Ethnicity. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 629-642.	2.5	122
576	ACOG. Obstetrics and Gynecology, 2019, 133, 1-1.	2.4	17
577	Mediation Models of Perceived Medical Heterosexism, Providerâ€“Patient Relationship Quality, and Cervical Cancer Screening in a Community Sample of Sexual Minority Women and Gender Nonbinary Adults. LGBT Health, 2019, 6, 77-86.	3.4	13
578	Maternal History of Cervical Surgery and Preterm Delivery: A Retrospective Cohort Study. Journal of Women's Health, 2019, 28, 1538-1542.	3.3	12
579	Automated Pap Smear Cervical Cancer Screening Using Deep Learning. , 2019, 2019, 7044-7048.		56
580	Results of a Pilot Study of a Mail-Based Human Papillomavirus Self-Testing Program for Underscreened Women From Appalachian Ohio. Sexually Transmitted Diseases, 2019, 46, 185-190.	1.7	14
581	Barriers to the Uptake of Cervical Cancer Screening and Treatment among Rural Women in Ghana. BioMed Research International, 2019, 2019, 1-8.	1.9	41
582	Machine Learning Classification of Cervical Tissue Liquid Based Cytology Smear Images by Optomagnetic Imaging Spectroscopy. Tehnicki Vjesnik, 2019, 26, .	0.2	2
583	Clinical Controversies in Cervical Cancer Screening. Clinical Obstetrics and Gynecology, 2019, 62, 644-655.	1.1	2
584	Role of Screening History in Clinical Meaning and Optimal Management of Positive Cervical Screening Results. Journal of the National Cancer Institute, 2019, 111, 820-827.	6.3	20
585	Comparison of CerviHPV and Hybrid Capture 2 HPV tests for detection of highâ€“risk HPV infection in cervical swab specimens. Diagnostic Cytopathology, 2019, 47, 439-444.	1.0	6

#	ARTICLE	IF	CITATIONS
586	Human Papillomavirus Infection and Cervical Cancer in HIV+ Women. <i>Cancer Treatment and Research</i> , 2019, 177, 105-129.	0.5	9
587	The relationship between menopausal women infected with the human immunodeficiency virus and cervical atrophy: A cytologic study. <i>Diagnostic Cytopathology</i> , 2019, 47, 302-306.	1.0	0
588	Understanding Patients' Perspectives and Information Needs Following a Positive Home Human Papillomavirus Self-Sampling Kit Result. <i>Journal of Women's Health</i> , 2019, 28, 384-392.	3.3	23
589	A blueprint for cancer screening and early detection: Advancing screening's contribution to cancer control. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 50-79.	329.8	84
590	Prevalence of high-risk human papilloma virus in liquid-based cervical samples from Turkish women with normal and abnormal cytology. <i>Diagnostic Cytopathology</i> , 2019, 47, 100-104.	1.0	7
591	Cervical Cancer and Its Precursors. <i>Primary Care - Clinics in Office Practice</i> , 2019, 46, 117-134.	1.6	42
592	Diagnostic performance of the E6/E7 mRNA-based Optimygene HR-HPV RT-qDx assay for cervical cancer screening. <i>International Journal of Infectious Diseases</i> , 2019, 78, 22-30.	3.3	6
593	Interaction between TP53 and XRCC1 increases susceptibility to cervical cancer development: a case control study. <i>BMC Cancer</i> , 2019, 19, 24.	2.6	16
594	Cervical cancer screening research in the PROSPR I consortium: Rationale, methods and baseline findings from a US cohort. <i>International Journal of Cancer</i> , 2019, 144, 1460-1473.	5.1	20
595	Human Papillomavirus (HPV) Testing on Cervical Cytology Specimens. , 2019, , 199-221.		0
596	Patient knowledge and attitudes toward cervical cancer screening after the 2012 screening guidelines. <i>Patient Education and Counseling</i> , 2019, 102, 411-415.	2.2	5
597	Expectant management surveillance for patients at risk for invasive squamous cell carcinoma of the anus: a large US healthcare system experience. <i>International Journal of Colorectal Disease</i> , 2019, 34, 47-54.	2.2	24
598	Analytical performance of a low-cost multiplex polymerase chain reaction human papillomavirus genotyping assay for use in Sub-Saharan Africa. <i>Journal of Medical Virology</i> , 2019, 91, 308-316.	5.0	6
599	Circular RNAs: A novel biomarker for cervical cancer. <i>Journal of Cellular Physiology</i> , 2020, 235, 718-724.	4.1	120
600	Role of Ancillary Techniques in Gynecologic Cytopathology Specimens. <i>Acta Cytologica</i> , 2020, 64, 63-70.	1.3	4
601	Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting. <i>International Journal of Cancer</i> , 2020, 146, 617-626.	5.1	5
602	Human Papillomavirus (HPV) 16 and 18/45 Genotyping-Directed Follow-up of Women With Messenger RNA HPV-Positive, Cytology-Negative Cervical Screening Test Results. <i>American Journal of Clinical Pathology</i> , 2020, 153, 243-250.	0.7	9
603	Cancers of the Cervix, Vulva, and Vagina. , 2020, , 1468-1507.e8.		5

#	ARTICLE	IF	CITATIONS
604	Incidence of abnormal cervical and vaginal cytology among women over age 65 years living with human immunodeficiency virus. American Journal of Obstetrics and Gynecology, 2020, 222, 486.e1-486.e10.	1.3	5
605	Three large scale surveys highlight the complexity of cervical cancer under-screening among women 45-65 years of age in the United States. Preventive Medicine, 2020, 130, 105880.	3.4	27
606	Cancer statistics, 2020. Ca-A Cancer Journal for Clinicians, 2020, 70, 7-30.	329.8	16,450
607	Primary HPV testing with cytology versus cytology alone in cervical screening- A prospective randomized controlled trial with two rounds of screening in a Chinese population. International Journal of Cancer, 2020, 147, 1152-1162.	5.1	16
608	Cost-effectiveness studies of HPV self-sampling: A systematic review. Preventive Medicine, 2020, 132, 105953.	3.4	57
609	Analysis of HPV genotype-specific concordance between EUROArray HPV and HPV 3.5 LCD-Array Kit in cervical samples of 163 patients. Archives of Gynecology and Obstetrics, 2020, 301, 745-751.	1.7	1
610	In the hands of nurses: A focus group study of how nurses perceive and promote inpatients' needs for physical activity. Nursing Open, 2020, 7, 334-344.	2.4	3
611	Prevalence of Potentially Unnecessary Bimanual Pelvic Examinations and Papanicolaou Tests Among Adolescent Girls and Young Women Aged 15-20 Years in the United States. JAMA Internal Medicine, 2020, 180, 274.	5.1	21
612	Impact of screening on cervical cancer incidence: A population-based case-control study in the United States. International Journal of Cancer, 2020, 147, 887-896.	5.1	20
613	The effect of web-based education on Pap smear behaviours of teachers. European Journal of Cancer Care, 2020, 29, e13202.	1.5	6
614	Screening and Early Detection. , 2020, , 375-398.e7.		1
615	Analysis of the role of the human papillomavirus 16/18 E7 protein assay in screening for cervical intraepithelial neoplasia: a case control study. BMC Cancer, 2020, 20, 999.	2.6	7
616	<p>The Triage Effectiveness of an Extended High-Risk Human Papillomavirus Genotyping Assay for Women with Cytology Showing Atypical Squamous Cells of Undetermined Significance in China</p>. Risk Management and Healthcare Policy, 2020, Volume 13, 1747-1756.	2.5	3
617	Long noncoding RNAs (lncRNAs) in cervical carcinogenesis: New molecular targets, current prospects. Critical Reviews in Oncology/Hematology, 2020, 156, 103111.	4.4	15
618	A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States. Gynecologic Oncology, 2020, 159, 344-353.	1.4	9
619	Opposition to Pharmacist Contraception Services: Evidence for Rebuttal. Pharmacy (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 5	1.6	7
620	Understanding User Acceptance of Clinical Decision Support Systems to Promote Increased Cancer Screening Rates in a Primary Care Practice. Journal of Primary Care and Community Health, 2020, 11, 215013272095883.	2.1	7
621	Effect of Health Education on Women's Knowledge Level about Pap Smear's Early Detection of Cervical Cancer Prevention. Asian Journal of Oncology, 0, 06, 65-71.	0.2	4

#	ARTICLE	IF	CITATIONS
622	Cytology and curetting diagnosis of endocervical adenocarcinoma. Journal of the American Society of Cytopathology, 2020, 9, 556-562.	0.5	4
623	An Evaluation of Breast and Cervical Cancer Screening Outcomes in an Education and Patient Navigation Program in Rural and Border Texas. Journal of Cancer Education, 2022, 37, 1043-1052.	1.3	7
624	Cervical Cancer Screening Guidelines in the Postvaccination Era: Review of the Literature. Journal of Oncology, 2020, 2020, 1-14.	1.3	22
625	Transgender patients: considerations for routine gynecologic care and cancer screening. International Journal of Gynecological Cancer, 2020, 30, 1990-1996.	2.5	17
626	Overexpression of programmed cell death ligand 1 in patients with CIN and its correlation with human papillomavirus infection and CIN persistence. Infectious Agents and Cancer, 2020, 15, 47.	2.6	5
627	Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. Ca-A Cancer Journal for Clinicians, 2020, 70, 321-346.	329.8	481
628	Liquid-based cytology for the detection of cervical intraepithelial lesions in Jimma town, Ethiopia. BMC Cancer, 2020, 20, 706.	2.6	7
629	County-Level Poverty and Barriers to Breast and Cervical Cancer Screening in a Health Education and Patient Navigation Program for Rural and Border Texas Residents. Journal of Cancer Education, 2022, 37, 421-429.	1.3	5
630	An RCT to Increase Breast and Colorectal Cancer Screening. American Journal of Preventive Medicine, 2020, 59, e69-e78.	3.0	10
631	Classification of cervical neoplasms on colposcopic photography using deep learning. Scientific Reports, 2020, 10, 13652.	3.3	43
632	Evaluaci3n del virus del papiloma humano en varones: primera revisi3n exhaustiva de la literatura. Actas Urol3gicas Espa±olas, 2020, 44, 86-93.	0.7	8
633	Persistent High-Risk HPV Infection and Molecular Changes Related to the Development of Cervical Cancer. Case Reports in Obstetrics and Gynecology, 2020, 2020, 1-6.	0.3	8
634	Cancer Prevention and Screening for Older Adults: Part 2. Interventions to Prevent and Screen for Breast, Prostate, Cervical, Ovarian, and Endometrial Cancer. Journal of the American Geriatrics Society, 2020, 68, 2684-2691.	2.6	8
635	Cost-effectiveness and accuracy of cervical cancer screening with a high-risk HPV genotyping assay vs a nongenotyping assay in China: an observational cohort study. Cancer Cell International, 2020, 20, 421.	4.1	6
636	Interventions to increase breast and cervical cancer screening uptake among rural women: a scoping review. Cancer Causes and Control, 2020, 31, 965-977.	1.8	14
637	Extended HPV Genotyping to Compare HPV Type Distribution in Self- and Provider-Collected Samples for Cervical Cancer Screening. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2651-2661.	2.5	8
638	A hidden Markov model for population-level cervical cancer screening data. Statistics in Medicine, 2020, 39, 3569-3590.	1.6	11
639	Type-specific Distribution of Cervical hrHPV Infection and the Association with Cytological and Histological Results in a Large Population-based Cervical Cancer Screening Program: Baseline and 3-year Longitudinal Data. Journal of Cancer, 2020, 11, 6157-6167.	2.5	7

#	ARTICLE	IF	CITATIONS
640	An Automatic Mass Screening System for Cervical Cancer Detection Based on Convolutional Neural Network. Mathematical Problems in Engineering, 2020, 2020, 1-14.	1.1	8
641	Evaluation of the SureX HPV genotyping test for the detection of high-risk HPV in cervical cancer screening. Virology Journal, 2020, 17, 171.	3.4	3
642	Estimating the impact of increasing cervical cancer screening in the National Breast and Cervical Cancer Early Detection Program among low-income women in the USA. Cancer Causes and Control, 2020, 31, 691-702.	1.8	10
643	MobileNetV2 Ensemble for Cervical Precancerous Lesions Classification. Processes, 2020, 8, 595.	2.8	33
644	Test Accuracy of Human Papillomavirus in Urine for Detection of Cervical Intraepithelial Neoplasia. Journal of Clinical Microbiology, 2020, 58, .	3.9	18
645	What Constitutes Optimal Cervical Screening for Young Women Ages 21 to 29 Years?. American Journal of Clinical Pathology, 2020, 153, 712-714.	0.7	0
646	HPV detection rates and histopathologic follow-up of patients with HSIL cytology in a large academic women's hospital laboratory. Journal of the American Society of Cytopathology, 2020, 9, 550-555.	0.5	6
647	Moving forward—the 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors and beyond: implications and suggestions for laboratories. Journal of the American Society of Cytopathology, 2020, 9, 291-303.	0.5	21
648	The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples. PLoS ONE, 2020, 15, e0234518.	2.5	15
649	Koilocytic changes are not elicited by human papillomavirus genotypes with higher oncogenic potential. Journal of Medical Virology, 2020, 92, 3766-3773.	5.0	7
650	EMR-Based Intervention Improves Cervical Cancer Screening Rate in a Primary Care Office. American Journal of Medical Quality, 2020, 35, 505-505.	0.5	0
651	Prevalence of Inadequate Cervical Cancer Screening in Low-Income Older Women. Journal of Women's Health, 2020, 29, 1350-1353.	3.3	5
652	A Survey for Cervical Cytopathology Image Analysis Using Deep Learning. IEEE Access, 2020, 8, 61687-61710.	4.2	77
653	Racial and Ethnic Differences in Acceptability of Urine and Cervico-Vaginal Sample Self-Collection for HPV-Based Cervical Cancer Screening. Journal of Women's Health, 2020, 29, 971-979.	3.3	19
654	<p>>CFTR Regulates the Proliferation, Migration and Invasion of Cervical Cancer Cells by Inhibiting the NF-κB Signalling Pathway</p>. Cancer Management and Research, 2020, Volume 12, 4685-4697.	1.9	11
655	National Policies to Prevent and Manage Cervical Cancer in East African Countries: A Policy Mapping Analysis. Cancers, 2020, 12, 1520.	3.7	10
656	Contributions of Liquid-Based (Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical Cancer and Precancer in the United States. American Journal of Clinical Pathology, 2020, 154, 510-516.	0.7	35
657	Defining benchmarks for tolerable risk thresholds in cancer screening: Impact of HPV vaccination on the future of cervical cancer screening. International Journal of Cancer, 2020, 147, 3305-3312.	5.1	12

#	ARTICLE	IF	CITATIONS
658	Cervical cancer screening behaviors and proximity to federally qualified health centers in South Carolina. <i>Cancer Epidemiology</i> , 2020, 65, 101681.	1.9	4
659	The role of human papilloma virus test in men: First exhaustive review of literature. <i>Actas Urológicas Españolas (English Edition)</i> , 2020, 44, 86-93.	0.2	0
660	Human Papillomavirus 16/18-Associated Cervical Lesions: Differences by Area-Based Measures of Race and Poverty. <i>American Journal of Preventive Medicine</i> , 2020, 58, e149-e157.	3.0	4
661	Survival disparities in vulvar cancer patients in Commission on Cancer®-accredited facilities. <i>Gynecologic Oncology</i> , 2020, 157, 136-145.	1.4	7
662	Dominican Provider Practices for Cervical Cancer Screening in Santo Domingo and Monte Plata Provinces. <i>Journal of Cancer Education</i> , 2020, 36, 693-701.	1.3	1
663	Geographic and sociodemographic differences in cervical cancer screening modalities. <i>Preventive Medicine</i> , 2020, 133, 106014.	3.4	15
664	Incorporating Stakeholder Feedback in Guidelines Development for the Management of Abnormal Cervical Cancer Screening Tests. <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 167-177.	1.9	13
665	Are uninsured women in a national screening program having longer intervals between cervical cancer screening tests?. <i>Preventive Medicine</i> , 2020, 135, 106078.	3.4	2
666	Real-world data on cervical cancer risk stratification by cytology and HPV genotype to inform the management of HPV-positive women in routine cervical screening. <i>British Journal of Cancer</i> , 2020, 122, 1715-1723.	6.4	43
667	Vaginal carcinoma after cervical dysplasia. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 265-273.	2.5	0
668	Cervical Cancer Identification Based Texture Analysis Using GLCM-KELM on Colposcopy Data. , 2020, , .		8
669	Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women. <i>Cancer Prevention Research</i> , 2020, 13, 163-172.	1.5	11
670	Gynecologic Considerations for the Urologic Surgeon. <i>Urology</i> , 2021, 150, 116-124.	1.0	0
671	p16/ki67 and E6/E7 mRNA Accuracy and Prognostic Value in Triaging HPV DNA-Positive Women. <i>Journal of the National Cancer Institute</i> , 2021, 113, 292-300.	6.3	41
672	Is cervical cytology testing as a part of co-test unnecessary for HPV 16/18-infected women? A retrospective cohort study of 1647 women. <i>Diagnostic Cytopathology</i> , 2021, 49, 267-272.	1.0	2
673	Adjunctive testing by cytology, p16/Ki-67 dual-stained cytology or HPV16/18 E6 oncoprotein for the management of HPV16/18 screen-positive women. <i>International Journal of Cancer</i> , 2021, 148, 2264-2273.	5.1	4
674	Correlation of anal cytology with follow-up histology and Human Papillomavirus genotyping: A 10-year experience from an academic medical center. <i>Annals of Diagnostic Pathology</i> , 2021, 50, 151670.	1.3	3
675	Association of human papillomavirus genotype distribution and cervical cytology: a cross-sectional study. <i>Epidemiology and Infection</i> , 2021, 149, e95.	2.1	5

#	ARTICLE	IF	CITATIONS
676	Role of selected phytochemicals on gynecological cancers. , 2021, , 1-30.		0
677	General cancer screening practices among adult survivors of retinoblastoma: Results from the Retinoblastoma Survivor Study. Pediatric Blood and Cancer, 2021, 68, e28873.	1.5	2
678	Automatic model for cervical cancer screening based on convolutional neural network: a retrospective, multicohort, multicenter study. Cancer Cell International, 2021, 21, 35.	4.1	30
679	Diagnostic techniques for human papillomavirus detection for early diagnosis of endocervical adenocarcinoma. , 2021, 6, 6.	0.2	0
680	Cervical Cancer Screening Rate and Willingness among Female Migrants in Shenzhen, China: Three-Year Changes in Citywide Surveys. Cancer Research and Treatment, 2021, 53, 212-222.	3.0	6
681	The meaning of high-risk HPV other than type 16/18 in women with negative cytology: Is it really safe to wait for 1 year?. Diagnostic Cytopathology, 2021, 49, 480-486.	1.0	4
682	Interventions using mHealth strategies to improve screening rates of cervical cancer: A scoping review. Preventive Medicine, 2021, 143, 106387.	3.4	13
683	Performance Indicators of Cervical Cancer Screening Program Based on The Guidelines of Iran Ministry of Health and Medical Education. International Journal of Cancer Management, 2021, 14, .	0.4	2
684	What a patient needs to know about the virus human papillomas and cervical cancer?. Gynecology, 2021, 23, 83-87.	0.4	0
685	Obstetrician-gynecologists' practice patterns regarding HPV testing in cervical cancer screening in Turkey. Türk Jinekoloji Ve Obstetrik Dernei Dergisi, 2021, 18, 15-22.	0.8	0
686	Uterine Morcellation for Presumed Leiomyomas. Obstetrics and Gynecology, 2021, 137, e63-e74.	2.4	32
687	Analysis of the agreement between colposcopic impression and histopathological diagnosis of cervical biopsy in a single tertiary center of Chengdu. Archives of Gynecology and Obstetrics, 2021, 304, 1033-1041.	1.7	10
688	Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis. PLoS Medicine, 2021, 18, e1003534.	8.4	30
689	Servikal patoloji taraması ile merkezimize refere edilen hastaların değerlendirilmesi ve yönetimi. Türk Kadın Sağlığı Ve Neonatoloji Dergisi, 0, .	0.1	0
690	Joint effects of HPV-related knowledge and socio-demographic factors on HPV testing behaviour among females in Shenzhen. European Journal of Public Health, 2021, 31, 582-588.	0.3	5
691	American Cancer Society signals transition in cervical cancer screening from cytology to HPV tests. Cancer Cytopathology, 2021, 129, 259-261.	2.4	1
692	Overuse of Cervical Cancer Screening Tests Among Women With Average Risk in the United States From 2013 to 2014. JAMA Network Open, 2021, 4, e218373.	5.9	15
693	Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16INK4a immunostaining in China. BMC Infectious Diseases, 2021, 21, 400.	2.9	7

#	ARTICLE	IF	CITATIONS
694	Virus del papiloma humano (VPH) y cáncer. Medicina Y Laboratorio, 2021, 25, 467-483.	0.1	2
695	A colorimetric IsoPCR for the rapid and sensitive visual detection of high-risk HPV16 in clinical samples with hydroxynaphthol blue. Journal of Virological Methods, 2021, 290, 114072.	2.1	3
696	Gender-neutral HPV elimination, cervical cancer screening, and treatment: Experience from Bhutan. International Journal of Gynecology and Obstetrics, 2022, 156, 425-429.	2.3	10
697	LncRNA DLEU2 promotes cervical cancer cell proliferation by regulating cell cycle and NOTCH pathway. Experimental Cell Research, 2021, 402, 112551.	2.6	21
698	Updated Review of Major Cancer Risk Factors and Screening Test Use in the United States in 2018 and 2019, with a Focus on Smoking Cessation. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1287-1299.	2.5	34
700	Cervical cancer screening among sexual minority women: findings from a national survey. Cancer Causes and Control, 2021, 32, 911-917.	1.8	10
701	Viruses and Skin Cancer. International Journal of Molecular Sciences, 2021, 22, 5399.	4.1	12
702	Genotype-specific prevalence of human papillomavirus infection in asymptomatic Peruvian women: a community-based study. BMC Research Notes, 2021, 14, 172.	1.4	2
703	Deciphering Pap Guidelines and Determining Management in Primary Care. Advances in Family Practice Nursing, 2021, 3, 95-109.	0.1	0
704	Classification of cervical cancer using Deep Learning Algorithm. , 2021, , .		25
705	Psychological factors among Appalachian women with abnormal Pap results. Journal of Rural Health, 2022, 38, 382-390.	2.9	3
706	Improving Breast and Cervical Cancer Screening Compliance Through Direct Physician Contact in a Military Treatment Facility: A Non-randomized Pilot Study. Military Medicine, 2021, 186, e480-e485.	0.8	1
707	Noninvasive Point-of-Care Nanobiosensing of Cervical Cancer as an Auxiliary to Pap-Smear Test. ACS Applied Bio Materials, 2021, 4, 5378-5390.	4.6	10
708	The p16/ki-67 assay is a safe, effective and rapid approach to triage women with mild cervical lesions. PLoS ONE, 2021, 16, e0253045.	2.5	8
709	Mapping evidence on management of cervical cancer in sub-Saharan Africa: scoping review protocol. Systematic Reviews, 2021, 10, 180.	5.3	3
710	Tendencias temporales del cáncer de cuello uterino invasivo en mujeres entre 20 y 39 años en Manizales, Colombia. 2003-2018. Revista Médica De Risaralda, 2021, 27, .	0.1	0
711	Cric searchable image database as a public platform for conventional pap smear cytology data. Scientific Data, 2021, 8, 151.	5.3	22
712	Vaginal intraepithelial neoplasia in patients after total hysterectomy. Current Problems in Cancer, 2021, 45, 100687.	2.0	15

#	ARTICLE	IF	CITATIONS
713	Real-world effectiveness of primary screening with high-risk human papillomavirus testing in the cervical cancer screening programme in China: a nationwide, population-based study. BMC Medicine, 2021, 19, 164.	5.5	26
714	Transgender Medicine and Hormone Therapy. Clinical Obstetrics and Gynecology, 2021, Publish Ahead of Print, 739-756.	1.1	0
715	Uterine cervical neoplasms mass screening at the University Hospital Centre of Libreville, Gabon: Associated factors with precancerous and cancerous lesions. PLoS ONE, 2021, 16, e0255289.	2.5	0
716	Validation of the indication for colposcopy proposed by the 2019 ASCCP risk-based management consensus guidelines: A single-center study in China. PLoS ONE, 2021, 16, e0253493.	2.5	0
717	Electrochemical Sensors for Detection of Markers on Tumor Cells. International Journal of Molecular Sciences, 2021, 22, 8184.	4.1	15
718	Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recommendations and Reports, 2021, 70, 1-187.	61.1	841
719	Prevalence and genotype distribution of human papillomavirus among 29Â263 women from the Longgang community of Shenzhen. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, , .	1.8	2
720	Diagnostic performance of HPV E6 / E7 mRNA testing towards HPV â€•DNA testing and p16 /Ki67 immunostaining as a biomarker of highâ€•risk HPV recurrence in Greek women surgically treated for their cervical lesions. Journal of Obstetrics and Gynaecology Research, 2021, 47, 3607-3617.	1.3	0
721	Exploring the barriers to Pap smear test in Iranian women: a qualitative study. BMC Women's Health, 2021, 21, 287.	2.0	9
722	Evaluation of p16INK4a immunocytology and human papillomavirus (HPV) genotyping triage after primary HPV cervical cancer screening on self-samples in China. Gynecologic Oncology, 2021, 162, 322-330.	1.4	3
723	Deep Auto Encoder Based Extreme Learning System for Automatic Segmentation of Cervical Cells. IETE Journal of Research, 2023, 69, 4066-4086.	2.6	8
724	The Impact of the Human Papillomavirus Vaccine on High-Grade Cervical Lesions in Urban and Rural Areas: An Ageâ€•Periodâ€•Cohort Analysis. Cancers, 2021, 13, 4215.	3.7	2
725	Impact of screening between the ages of 60 and 64 on cumulative rates of cervical cancer to age 84y by screening history at ages 50 to 59: A population-based case-control study. Preventive Medicine, 2021, 149, 106625.	3.4	8
726	Performance of DNA methylationâ€•based biomarkers in the cervical cancer screening program of northern Portugal: A feasibility study. International Journal of Cancer, 2021, 149, 1916-1925.	5.1	7
727	Trends in the use of cervical cancer screening tests in a large medical claims database, United States, 2013â€•2019. Gynecologic Oncology, 2021, 163, 378-384.	1.4	14
728	Pooled Cohort Equations and the competing risk of cardiovascular disease versus cancer: Multi-Ethnic study of atherosclerosis. American Journal of Preventive Cardiology, 2021, 7, 100212.	3.0	6
729	Socioeconomic Disparity Trends in Cancer Screening Among Women After Introduction of National Quality Indicators. Annals of Family Medicine, 2021, 19, 396-404.	1.9	4
730	De-implementation and substitution of clinical care processes: stakeholder perspectives on the transition to primary human papillomavirus (HPV) testing for cervical cancer screening. Implementation Science Communications, 2021, 2, 108.	2.2	5

#	ARTICLE	IF	CITATIONS
731	Rural-urban differences in HPV testing for cervical cancer screening. Journal of Rural Health, 2022, 38, 409-415.	2.9	9
732	A retrospective study of cytology and HPV genotypes results of 3229 vaginal intraepithelial neoplasia patients. Journal of Medical Virology, 2022, 94, 737-744.	5.0	17
733	Uptake of co-testing with HPV and cytology for cervical screening: A population-based evaluation in the United States. Gynecologic Oncology, 2021, 162, 555-559.	1.4	11
734	Impact of COVID-19 on cervical cancer screening: Challenges and opportunities to improving resilience and reduce disparities. Preventive Medicine, 2021, 151, 106596.	3.4	68
735	Identification of volatile organic compounds in the urine of patients with cervical cancer. Test concept for timely screening. Clinica Chimica Acta, 2021, 522, 132-140.	1.1	6
736	Evaluation of Pre-malignant Lesions of the Uterine Cervix by Shear Wave Elastography: A New Diagnostic Tool. Ultrasound in Medicine and Biology, 2021, 47, 3275-3282.	1.5	1
737	Expression and clinical significance of UBE2V1 in cervical cancer. Biochemistry and Biophysics Reports, 2021, 28, 101108.	1.3	1
738	History, physical examination, and preventive health care. , 2022, , 127-139.e2.		0
739	Predictors of timely diagnostic follow-up after an abnormal Pap test among Hispanic women seeking care in El Paso, Texas. BMC Women's Health, 2021, 21, 11.	2.0	8
740	Risk Assessment Approach to Management. , 2015, , 305-313.		3
741	Cervical Cancer Among Asian Americans. , 2016, , 271-285.		1
742	Exhaled breath online measurement for cervical cancer patients and healthy subjects by proton transfer reaction mass spectrometry. Analytical and Bioanalytical Chemistry, 2017, 409, 5603-5612.	3.7	21
743	Cancers of the Cervix, Vulva, and Vagina. , 2014, , 1534-1574.e8.		7
744	Prevalence and genotype distribution of human papillomavirus among women with cervical lesions in Shenzhen city, China. Human Vaccines and Immunotherapeutics, 2021, 17, 965-971.	3.3	16
745	Improving Cervical Precancer Surveillance: Validity of Claims-Based Prediction Models in ICD-9 and ICD-10 Eras. JNCI Cancer Spectrum, 2021, 5, pkaa112.	2.9	3
746	Optical coherence tomography in gynecology: a narrative review. Journal of Biomedical Optics, 2017, 22, 1.	2.6	12
747	Human Papillomaviruses. , 0, , 1783-1802.		1
748	Molecular Microbiology. , 0, , 54-90.		4

#	ARTICLE	IF	CITATIONS
749	Multicentric study of cervical cancer screening with human papillomavirus testing and assessment of triage methods in Latin America: the ESTAMPA screening study protocol. <i>BMJ Open</i> , 2020, 10, e035796.	1.9	17
750	Pathological discrepancy between colposcopic directed cervical biopsy and conisation results: A five years experience of a single center in Turkey. <i>Pakistan Journal of Medical Sciences</i> , 2019, 35, 1627-1630.	0.6	1
751	Comparative analysis of robotic <i>vs</i> laparoscopic radical hysterectomy for cervical cancer. <i>World Journal of Clinical Cases</i> , 2019, 7, 3185-3193.	0.8	17
752	Significance of HPV-58 Infection in Women Who Are HPV-Positive, Cytology-Negative and Living in a Country with a High Prevalence of HPV-58 Infection. <i>PLoS ONE</i> , 2013, 8, e58678.	2.5	15
753	Cervical Cytology Specimen Stability in Surepath Preservative and Analytical Sensitivity for HPV Testing with the cobas and Hybrid Capture 2 Tests. <i>PLoS ONE</i> , 2016, 11, e0149611.	2.5	5
754	Factors Associated with Uptake of Visual Inspection with Acetic Acid (VIA) for Cervical Cancer Screening in Western Kenya. <i>PLoS ONE</i> , 2016, 11, e0157217.	2.5	22
755	Prognostic Impact of Epidermal Growth Factor Receptor Overexpression in Patients with Cervical Cancer: A Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0158787.	2.5	29
756	Incidence rates and temporal trends of cervical cancer relating to opportunistic screening in two developed metropolitan regions of Brazil: a population-based cohort study. <i>Sao Paulo Medical Journal</i> , 2019, 137, 322-328.	0.9	3
757	Diagnostic accuracy of high-risk HPV genotyping in women with high-grade cervical lesions: evidence for improving the cervical cancer screening strategy in China. <i>Oncotarget</i> , 2016, 7, 83775-83783.	1.8	22
758	Utility of gene methylation analysis, cytological examination, and HPV-16/18 genotyping in triage of high-risk human papilloma virus-positive women. <i>Oncotarget</i> , 2017, 8, 62274-62285.	1.8	32
759	A cocktail of p16INK4a and Ki-67, p16INK4a and minichromosome maintenance protein 2 as triage tests for human papillomavirus primary cervical cancer screening. <i>Oncotarget</i> , 2017, 8, 83890-83899.	1.8	9
760	CUL2 overexpression driven by CUL2/E2F1/miR-424 regulatory loop promotes HPV16 E7 induced cervical carcinogenesis. <i>Oncotarget</i> , 2016, 7, 31520-31533.	1.8	19
761	Economic evaluation of cervical cancer screening strategies in urban China. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 974-983.	2.2	8
762	Value of multi-quadrants biopsy: Pooled analysis of 11 population-based cervical cancer screening studies. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 383-394.	2.2	4
763	The Study of Pap Smear Conduction and its Related Factors Based on Health Belief Model in Women Referring to Health Care Centers in Qom During 2014. <i>Journal of Education and Community Health</i> , 2017, 2, 25-33.	0.7	12
764	Cervical Cancer Screening in Resource-Constrained Countries: Current Status and Future Directions. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 1461-1467.	1.2	31
765	Significance of immunohistochemical expression of p16INK4a in the differentiation of inflammatory and preneoplastic cervical lesions. <i>Srpski Arhiv Za Celokupno Lekarstvo</i> , 2015, 143, 42-49.	0.2	3
767	Evidence based appropriate triage strategies for implementing high risk HPV as primary technology in cervical cancer screening. <i>Minerva Ginecologica</i> , 2020, 72, 96-105.	0.8	4

#	ARTICLE	IF	CITATIONS
768	Examining Cervical Cancer Screening Utilization Among African Immigrant Women: A Literature Review. <i>International Journal of Women's Health and Wellness</i> , 2017, 3, .	0.1	5
769	PECULIARITIES OF MICROBIOCENOSIS OF THE URINARY GENERAL SYSTEM OF WOMEN IN PATHOLOGICAL CONDITIONS. <i>Bulletin of Problems Biology and Medicine</i> , 2019, 1, 189.	0.1	1
770	Saudi Women's Knowledge and Attitude toward Cervical Cancer Screening, Treatment, and Prevention: A Cross-Sectional Study in Qassim Region (2018-2019). <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 2965-2969.	1.2	19
771	Reduced Expression of IL-1 β and IL-18 Proinflammatory Interleukins Increases the Risk of Developing Cervical Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 2715-2721.	1.2	15
772	Knowledge, Attitudes, and Practices Regarding Cervical Cancer Screening among HIV-infected Women at Srinagarind Hospital: A Cross-Sectional Study. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 2979-2986.	1.2	2
773	National screening programs for cervical cancer in Asian countries. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e55.	2.2	52
774	LncRNA ANCR downregulates hypoxia-inducible factor β and inhibits the growth of HPV-negative cervical squamous cell carcinoma under hypoxic conditions. <i>Molecular Medicine Reports</i> , 2020, 21, 413-419.	2.4	4
775	Breast and Cervical Cancer Screening among US and non US Born African American Muslim Women in New York City. <i>AIMS Public Health</i> , 2017, 4, 78-93.	2.6	18
776	Disparities in cervical cancer in African American women: What primary care physicians can do. <i>Cleveland Clinic Journal of Medicine</i> , 2017, 84, 788-794.	1.3	7
777	Can automated alerts within computerized physician order entry improve compliance with laboratory practice guidelines for ordering Pap tests?. <i>Journal of Pathology Informatics</i> , 2014, 5, 37.	1.7	17
778	Individualized Bayesian Risk Assessment for Cervical Squamous Neoplasia. <i>Journal of Pathology Informatics</i> , 2020, 11, 9.	1.7	4
779	The Impact of High-Risk HPV Genotypes Other Than HPV 16/18 on the Natural Course of Abnormal Cervical Cytology: A Korean HPV Cohort Study. <i>Cancer Research and Treatment</i> , 2016, 48, 1313-1320.	3.0	20
780	The Mitochondrial Antisense ncRNAs are Down-Regulated in Early Cervical Carcinoma. <i>Journal of Cancer Science & Therapy</i> , 2012, 01, .	1.7	3
781	Prevention of Cervical Cancer in Women: Human Papillomavirus DNA Testing in Atypical Pap Smears. <i>Journal of Virology & Antiviral Research</i> , 2013, 02, .	0.1	4
782	Sociodemographic inequalities in the uptake of Papanicolaou tests in Peru: Analysis of the Demographic and Family Health Survey 2015-2017. <i>Epidemiology and Health</i> , 2020, 42, e2020043.	1.9	3
783	Attend to the "Small Stuff": State Policy Issues Affecting Cervical Cancer Efforts. <i>Open Journal of Obstetrics and Gynecology</i> , 2014, 04, 455-461.	0.2	4
784	Use of Liquid-Based Cytology (LBC) and Cell Blocks from Cell Remnants for Cytologic, Immunohistochemical, and Immunocytochemical Diagnosis of Malignancy. <i>Open Journal of Pathology</i> , 2012, 02, 58-65.	0.2	11
785	Challenges and Recommendations to Recruiting Women Who Do Not Adhere to Follow-Up Gynecological Care. <i>Open Journal of Preventive Medicine</i> , 2014, 04, 123-128.	0.3	4

#	ARTICLE	IF	CITATIONS
786	Diffusion weighted imaging in gynecological malignancies - present and future. World Journal of Radiology, 2016, 8, 288.	1.1	16
787	Cervical cancer screening in Switzerland: time to rethink the guidelines. Swiss Medical Weekly, 2015, 145, w14112.	1.6	11
788	Awareness of Cervical Cancer among Couples in a Slum Area of Mumbai. Asian Pacific Journal of Cancer Prevention, 2012, 13, 4901-4903.	1.2	15
789	Agreement between Colposcopic Diagnosis and Cervical Pathology: Siriraj Hospital Experience. Asian Pacific Journal of Cancer Prevention, 2014, 15, 423-426.	1.2	24
790	Evaluation of an Educational Program on Cervical Cancer for Rural Women in Mangalore, Southern India. Asian Pacific Journal of Cancer Prevention, 2014, 15, 6603-6608.	1.2	9
791	Health Disparities between Black Hispanic and Black Non-Hispanic Cervical Cancer Cases in the USA. Asian Pacific Journal of Cancer Prevention, 2014, 15, 9719-9723.	1.2	13
792	Accuracy of Combined Visual Inspection with Acetic Acid and Cervical Cytology Testing as a Primary Screening Tool for Cervical Cancer: a Systematic Review and Meta-Analysis. Asian Pacific Journal of Cancer Prevention, 2015, 16, 5889-5897.	1.2	7
793	Cervical Cancer Screening: Recommendations for Muslim Societies. Asian Pacific Journal of Cancer Prevention, 2016, 17, 239-247.	1.2	8
794	Adapting Cervical Dysplasia Screening, Treatment and Prevention Approaches to Low Resource Settings. International STD Research & Reviews, 2013, 1, 39-48.	0.2	2
795	The Risk Stratification for Cervical Cancer and Precursors of Domestic HPV Testing With HPV 16/18 Genotyping in Women With NILM Cytology in Central China: A Cohort Study. Frontiers in Oncology, 2021, 11, 716762.	2.8	3
796	Epigenetic approaches for cervical neoplasia screening (Review). Experimental and Therapeutic Medicine, 2021, 22, 1481.	1.8	10
798	Prevalence of Cervical Cellular Abnormalities by Liquid Based Cytology in Taif Province : A Hospital Based Study. The Egyptian Journal of Hospital Medicine, 2013, , 678-684.	0.1	0
800	Critical Analysis of Cervical and Endometrial Biopsy Specimens. Medical Journal of Shree Birendra Hospital, 2013, 12, 23-28.	0.0	0
801	Prevalence of Human Papillomavirus (HPV) Genotypes and Multiple Infections in Routine Cervical Cancer Screening in a Spanish Regional Population. SOJ Microbiology & Infectious Diseases, 2013, 1, .	0.7	0
802	Assessment of Women's Knowledge of Endometrial Cancer. Gynecology & Obstetrics (Sunnyvale, Calif) Tj ETQq0 0.0 rgBT /O verlock 10 0.1	0.1	0
803	Cancer Prevention, Screening, and Early Detection. , 2014, , 322-359.e12.		1
804	Comparison of cervical cytological screening results between postmenopausal and elderly women. Turk Patoloji Dergisi, 2014, 30, 38.	0.3	4
805	Human Papillomavirus: Epidemiology and Clinical Features of Related Cancer. , 2014, , 199-228.		1

#	ARTICLE	IF	CITATIONS
826	Preinvasive Lesions in Pregnancy and Menopause. , 2017, , 143-154.		0
827	Prevention of Complications from Human Papillomavirus Infection in the HIV-Infected Individual. , 2017, , 141-163.		0
828	Gynecologic Cytology. , 2017, , 13-43.		0
829	SaÄŸlÄ±k Ä±alÄ±ÅŸanlarÄ±nÄ±n Kanser TaramalarÄ± HakkÄ±ndaki Bilgi, Tutum ve DavranÄ±ÅŸlarÄ±nÄ±n DeÄŸerlendirilmesi, Ankara Medical Journal, 2017, 17, .	0.1	14
830	The Evaluation of Cervical Cytology Results in a Tertiary Health Centre Between 2006-2015. Ankara Medical Journal, 0, , .	0.1	0
832	Screening for Cervical Cancer and Management of Its Precursor Lesions. , 2018, , 147-162.		0
833	Human Papillomavirus Types and Cancer Screening Guidelines. Journal of Infectious Diseases and Medicine, 2018, 03, .	0.1	0
834	Comorbidity in Aging and Cancer. , 2018, , 1-29.		0
835	Perceptions of Pap Screening in a Context of HPV Vaccination. International Journal of Women's Health and Reproduction Sciences, 2018, 6, 240-247.	0.4	0
836	CLINICAL AND ANAMNESTIC PREDICTORS OF DEVELOPMENT OF CERVICAL PATHOLOGY. ZbÄ±rnÄ±k NaukovÄ±h PracÄ± AsocÄ±acÄ±Ä± Ä±kuÄ±erÄ±v-gÄ±nekologÄ±v UkraÄ±ni, 2018, .	0.1	0
837	EVALUATION OF THE CYTOKINE STATUS IN PATIENTS WITH DIFFERENT VARIANTS OF THE COURSE OF HPV INFECTION. Kuban Scientific Medical Bulletin, 2018, 25, 43-50.	0.4	0
838	Chapter 27: Health Promotion, Disease Prevention, and Population Health. , 2018, , .		0
840	Cytology and HPV Testing in Primary Cervical Cancer Screening. , 2019, , 83-91.		0
842	New Strategies for Early Screening and Detection of Cervical Cancer. Advances in Clinical Medicine, 2019, 09, 867-870.	0.0	0
843	Prevalence of Unsatisfactory Pap Smear and Associated Clinical History and Diagnosis in a Tertiary Teaching Hospital in Ghana. Journal of Biomedical Science and Engineering, 2019, 12, 311-321.	0.4	1
844	Comparison of cervical cancer screening by visual inspection with acetic acid versus cervical-cytology in pregnancy. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 85-89.	0.2	1
845	Optimizing light delivery through ball-shaped multimode fiber tips in co-registered photoacoustic and ultrasound endo-cavity imaging: simulation and experimental validation. , 2019, , .		0
846	MolekÄ±ler Hpv Uygulanan Olgularda Hpv SonuÄŸlarÄ± ile Patolojik Materyallerin KarÄŸÄ±laÅŸtÄ±rÄ±lmasÄ±. Dicle Medical Journal, 0, , 167-172.	0.6	2

#	ARTICLE	IF	CITATIONS
847	COMPARATIVE ANALYSIS OF CONVENTIONAL AND LIQUID-BASED CYTOLOGICAL METHODS FOR CERVICAL SMEARS. Issledovaniya I Praktika V Medicine, 2019, 6, 83-90.	0.5	2
848	HPV and HPV-associated cervical diseases in women, who use hormonal methods of contraception: diagnostic and treatment management of abnormal cytology test result. Meditsinskiy Sovet, 2019, , 34-38.	0.5	1
850	Pap Smear and HPV Testing. , 2020, , 65-76.		2
851	Yüksek Riskli HPV Pozitif Sitolojik Sonuçlar, Kolposkopik Biyopsi Sonuçları ile Karşılaştırılması, Harran Üniversitesi Tıp Fakültesi Dergisi, 0, , .	0.3	0
852	Development of A Management Guideline Wheel for Abnormal Pap Smears and Related Cervical Pathology. Annals of Cytology and Pathology, 2020, 5, 013-034.	0.4	1
853	On both sides of the Atlantic. , 2020, , 72-92.		0
854	Clinical Features of Pathological Processes of the Cervix Associated with Human Papillomavirus Infection. Investigations in Gynecology Research & Womens Health (IGRWH), 2020, 3, .	0.0	0
855	Comparative Study of Cervical Pap Smear and Visual Inspection of The Cervix To Detect Premalignant Disease of The Cervix. Kurdistan Journal of Applied Research, 2020, 5, 210-217.	0.4	1
856	Evidence of Passive Smoking as a Risk Factor of High-Grade Squamous Intraepithelial Lesion: A Case-Control Study. Biological and Pharmaceutical Bulletin, 2020, 43, 1061-1066.	1.4	4
857	Accuracy of different triage strategies for human papillomavirus positivity in an Italian screening population. International Journal of Cancer, 2022, 150, 952-960.	5.1	2
859	Prevalence and genotype distribution of high-risk human papillomavirus infection among women with cervical cytological abnormalities in Chongqing, China, 2014-2020. Diagnostic Cytopathology, 2021, 49, 1237-1243.	1.0	4
860	Human Papillomavirus Vaccine Impact on Cervical Precancers in a Low-Vaccination Population. American Journal of Preventive Medicine, 2022, 62, 395-403.	3.0	1
861	Pap Smear and Mammogram Screening Rates in a Refugee and General OB/GYN Clinic: A Retrospective Review. Journal of Immigrant and Minority Health, 2021, , 1.	1.6	0
862	Cervical Dysplasia. , 2020, , 1213-1219.e2.		0
863	Interpreting a Diagnosis of Atypical Squamous Cells of Undetermined Significance in Cervical Cytology and its Association with Human Papillomavirus. Sultan Qaboos University Medical Journal, 2020, 20, e318-323.	1.0	2
864	Identifying Cancer Screening Adherence in the Emergency Department Utilizing Research Associates. Journal of Emergency Medicine, 2020, 59, 894-899.	0.7	4
865	Shape Mask Generator: Learning to Refine Shape Priors for Segmenting Overlapping Cervical Cytoplasms. Lecture Notes in Computer Science, 2020, , 639-649.	1.3	1
866	Sociodemographic and clinical profile of geriatric patients with cervical cancer—An audit from a tertiary cancer center in India. Journal of Family Medicine and Primary Care, 2020, 9, 1528.	0.9	1

#	ARTICLE	IF	CITATIONS
867	Comorbidity in Aging and Cancer. , 2020, , 365-393.		0
868	Mathematical analysis of a human papillomavirus transmission model with vaccination and screening. Mathematical Biosciences and Engineering, 2020, 17, 5449-5476.	1.9	9
869	Tumors of the Female Reproductive Organs. , 2020, , 1-15.		0
870	Evaluation of Different Guidelines for Cervical Cancer Screening and Management of Abnormal Cervical Cytology. Annals of Cytology and Pathology, 2020, 5, 001-012.	0.4	3
871	Clinical Experience in Management of Patients with Cervical Erosion and Ectopia. Open Access Macedonian Journal of Medical Sciences, 2020, 8, 226-230.	0.2	1
872	Trends in Precancerous Cervical Lesions by Area-Based Measures of Poverty, Race, and Ethnicity, Connecticut, 2008-2018. Public Health Reports, 2021, , 003335492110563.	2.5	0
873	XXXXXXXXXX Ėniversitesi Hastanesi KadĖn HastalĖkları ve DoĖyum PolikliniĖi'ne baĖvuran hastaların servikal smear sonuĖlarıĖn deĖlendirilmesi. Pamukkale Medical Journal, 0, , .	0.2	0
874	A comparison of highĖrisk human papillomavirus DNA detection between urine and cervical sample testing in women with abnormal Pap smears. Journal of Obstetrics and Gynaecology Research, 2021, , .	1.3	2
875	Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics. Preventive Medicine, 2022, 154, 106871.	3.4	3
876	Cervical cancer in the era of precision medicine: A perspective from developing countries. Advances in Cancer Biology Metastasis, 2021, 3, 100015.	2.0	0
877	Chapter 27: Health Promotion, Disease Prevention, and Population Health. , 2020, , .		0
879	Comparison of Age- Standard Incidence Rate Trends of Gynecologic and Breast Cancer in Iran and Other Countries. Iranian Journal of Public Health, 2014, 43, 1372-9.	0.5	11
880	Treatment patterns for cervical carcinoma in situ in Michigan, 1998-2003. Journal of Registry Management, 2013, 40, 84-92.	0.1	4
881	Improving the Utilization of Human Papillomavirus and Cervical Cytology Co-testing for Cervical Cancer Screening in an Obstetrics and Gynecology Resident Clinic. Hawai'i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health, 2015, 74, 267-9.	0.4	1
882	Health screening for older people-what are the current recommendations?. Malaysian Family Physician, 2015, 10, 2-10.	0.6	5
883	Psychosocial predictors of barriers to cervical cancer screening among Iranian women: the role of attachment style and social demographic factors. Journal of Preventive Medicine and Hygiene, 2013, 54, 218-22.	0.9	3
884	Medical home transformation and breast cancer screening. American Journal of Managed Care, 2016, 22, e382-e388.	1.1	7
885	Sexually transmitted diseases treatment guidelines, 2015. MMWR Recommendations and Reports, 2015, 64, 1-137.	61.1	1,132

#	ARTICLE	IF	CITATIONS
886	Evaluation of the risk of cervical cancer in patients with Multiple Sclerosis treated with cytotoxic agents: A cohort study. Iranian Journal of Neurology, 2018, 17, 64-70.	0.5	3
887	Screening for Human Papillomavirus-Associated Cervical Disease in HIV-Infected Women. Topics in Antiviral Medicine, 2015, 23, 142-5.	0.1	3
888	Knowledge and Attitude Toward Human Papillomavirus Infection and Vaccination among Thai Women: A Nationwide Social Media Survey. Asian Pacific Journal of Cancer Prevention, 2020, 21, 2895-2902.	1.2	1
889	Husband Support Mediates the Association between Self-Efficacy and Cervical Cancer Screening among Women in the Rural Area of Indonesia. Asia-Pacific Journal of Oncology Nursing, 2021, 8, 560-564.	1.6	0
890	A hybrid model for efficient cervical cell classification. Biomedical Signal Processing and Control, 2022, 72, 103288.	5.7	8
891	Is the aspect ratio of cells important in deep learning? A robust comparison of deep learning methods for multi-scale cytopathology cell image classification: From convolutional neural networks to visual transformers. Computers in Biology and Medicine, 2022, 141, 105026.	7.0	39
892	Effects of Continuous Catheterization on Reducing Postoperative Urinary Tract Infection in Cervical Cancer Patients with Double J Stent Placement. Journal of Healthcare Engineering, 2021, 2021, 1-7.	1.9	1
893	HPV and Pap testing among white, black, and hispanic women: results from a survey study. Discover Social Science and Health, 2021, 1, 1.	0.6	1
894	Prevalence characteristics of cervical human papillomavirus genotypes in Nanning, China: A 10-year survey of 77,756 women from one medical center. Journal of Medical Virology, 2022, 94, 2787-2795.	5.0	6
895	ThinPrep cytology combined with HPV detection in the diagnosis of cervical lesions in 1622 patients. PLoS ONE, 2021, 16, e0260915.	2.5	4
896	Development and Validation of the Medical Affairs Pharmaceutical Physician Value (MAPPval) Instrument. Pharmaceutical Medicine, 2022, 36, 47-57.	1.9	9
897	Comparative accuracy of cervical cancer screening strategies in healthy asymptomatic women: a systematic review and network meta-analysis. Scientific Reports, 2022, 12, 94.	3.3	12
898	Knowledge and Awareness toward Human Papillomavirus (HPV) and Cervical Cancer among Health College Students in the Northern Region of Saudi Arabia. Biosciences, Biotechnology Research Asia, 2020, 17, 579-585.	0.5	1
899	Psychometric Testing of Papanicolaou Testing Barriers and Self-efficacy Scales Among Black Women. Cancer Nursing, 2022, 45, E99-E106.	1.5	2
900	Knowledge and Attitude Toward Human Papillomavirus Infection and Vaccination among Thai Women: A Nationwide Social Media Survey. Asian Pacific Journal of Cancer Prevention, 2020, 21, 2895-2902.	1.2	3
901	Hormone Therapy in Transgender Men. , 2022, , 1668-1677.		0
902	Cancer statistics, 2022. Ca-A Cancer Journal for Clinicians, 2022, 72, 7-33.	329.8	10,001
903	A Case Report of Advanced Cervical Cancer in a Patient Non-compliant With Age-Appropriate Screening. Cureus, 2022, 14, e21744.	0.5	0

#	ARTICLE	IF	CITATIONS
904	Increasing the Take-Up of Public Health Services: An At-Scale Experiment on Digital Government. SSRN Electronic Journal, 0, , .	0.4	0
905	The Relationship Between Sexual Assault History and Cervical Cancer Screening Completion Among Women Veterans in the Veterans Health Administration. Journal of Women's Health, 2022, 31, 1040-1047.	3.3	5
906	Tumors of the Female Reproductive Organs. , 2022, , 1491-1505.		0
907	Factors Associated with Intention to Utilize Cervical Cancer Prevention Strategies among Pregnant Women Attending Antenatal Clinics in Ibadan, Nigeria. European Journal of Medical and Health Sciences, 2022, 4, 72-79.	0.2	0
908	Long non-coding RNA ZFAS1 regulates cell proliferation and invasion in cervical cancer via the miR-190a-3p/KLF6 axis. Bioengineered, 2022, 13, 3840-3851.	3.2	10
909	Predictors of time to death among cervical cancer patients at Tikur Anbesa specialized hospital from 2014 to 2019: A survival analysis. PLoS ONE, 2022, 17, e0264369.	2.5	14
910	Scrutinizing high-risk patients from ASCâ€US cytology via a deep learning model. Cancer Cytopathology, 2022, 130, 407-414.	2.4	4
911	Contribution of Etiologic Cofactors to CIN3+ Risk Among Women With Human Papillomavirusâ€Positive Screening Test Results. Journal of Lower Genital Tract Disease, 2022, 26, 127-134.	1.9	9
912	Effects of Menstrual Cycle on the Accumulation of Human Papillomavirus-Infected Cells Exfoliated from the Cervix That Drift into the Vagina. Microorganisms, 2022, 10, 693.	3.6	1
913	Knowledge, attitude and practice of female university students regarding human papillomavirus and self-sampling in KwaZulu-Natal, South Africa: a cross-sectional survey. BMC Women's Health, 2022, 22, 58.	2.0	4
914	LFANet: Lightweight feature attention network for abnormal cell segmentation in cervical cytology images. Computers in Biology and Medicine, 2022, 145, 105500.	7.0	15
915	Patterns of cervical cancer screening among Medicaid beneficiaries. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, , .	2.3	1
916	Knowledge, attitude and practice towards cervical cancer prevention among mothers of girls aged between 9 and 14Âyears: a cross sectional survey in Zimbabwe. BMC Women's Health, 2021, 21, 426.	2.0	3
917	Gaps and Opportunities to Improve Prevention of Human Papillomavirus-Related Cancers. Journal of Women's Health, 2021, 30, 1667-1672.	3.3	3
918	People aging with HIV â€protecting a population vulnerable to effects of COVID-19 and its control measures. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2022, 34, 1355-1363.	1.2	6
919	Husband Support Mediates the Association between Self-Efficacy and Cervical Cancer Screening among Women in the Rural Area of Indonesia. Asia-Pacific Journal of Oncology Nursing, 2021, 8, 560-564.	1.6	4
920	Cervical cancer screening. , 0, , 146-167.		0
922	Application effect of sevoflurane combined with remifentanyl intravenous inhalation anesthesia in patients undergoing laparoscopic radical resection of cervical cancer.. American Journal of Translational Research (discontinued), 2022, 14, 1034-1042.	0.0	0

#	ARTICLE	IF	CITATIONS
924	A Pyroptosis-Related Gene Panel for Predicting the Prognosis and Immune Microenvironment of Cervical Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 873725.	2.8	8
925	RGB Channel Superposition Algorithm with Acetowhite Mask Images in a Cervical Cancer Classification Deep Learning Model. <i>Sensors</i> , 2022, 22, 3564.	3.8	3
926	Cervical cancer screening guidelines and screening practices in 11 countries: A systematic literature review. <i>Preventive Medicine Reports</i> , 2022, 28, 101813.	1.8	19
927	REU-Net: Region-enhanced nuclei segmentation network. <i>Computers in Biology and Medicine</i> , 2022, 146, 105546.	7.0	10
928	Cervical and Vaginal Cytology. , 2014, , 1-57.		1
929	Performance of <sc>HPV E6</sc>/<sc>E7 mRNA</sc> assay as primary screening test: Results from the <sc>NTCC2</sc> trial. <i>International Journal of Cancer</i> , 2022, 151, 1047-1058.	5.1	21
930	Molecular Epidemiology of Human Papillomavirus Infection Among Chinese Women With Cervical Cytological Abnormalities. <i>Frontiers in Public Health</i> , 2022, 10, .	2.7	3
931	Current methods for preventing the development of cervical cancer in patients with papilloma viral infection. <i>Vestnik Dermatologii i Venerologii</i> , 2013, 89, 40-48.	0.6	1
932	Frequency Of Abnormal Papâ€™s Smears in Patients with Vaginal Discharge. <i>Pakistan Biomedical Journal</i> , 0, , 157-161.	0.1	0
933	DVT: Application ofÂDeep Visual Transformer inÂCervical Cell Image Classification. <i>Advances in Intelligent Systems and Computing</i> , 2022, , 285-294.	0.6	1
934	Early risk prediction of cervical cancer: A machine learning approach. , 2022, , .		17
935	Role of ProEx C immunocytochemistry in cervical high-grade squamous intraepithelial lesions detection. <i>Romanian Journal of Morphology and Embryology</i> , 2022, 62, 1029-1034.	0.8	1
936	Current Status of Human Papillomavirus Infection and Cervical Cancer in the Philippines. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	8
937	Temporal Trends in Cervical Cancer Screening Practices and Associated Downstream Abnormalities and Procedures Among Women With Insurance in the United States. <i>Obstetrics and Gynecology</i> , 2022, 140, 55-64.	2.4	0
938	Multi-class nucleus detection and classification using deep convolutional neural network with enhanced high dimensional dissimilarity translation model on cervical cells. <i>Biocybernetics and Biomedical Engineering</i> , 2022, 42, 797-814.	5.9	14
940	Predominant HPV Types From Cervical Swabs Determined by Molecular DNA Testing in a Period From 2018-2021 in Bosnia and Herzegovina. <i>Materia Socio-medica</i> , 2022, 34, 88.	0.7	0
941	Knowledge of human papilloma virus (HPV), HPV-vaccine and pap smear among adult Saudi women. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 2989.	0.9	3
942	AnÃ¡lisis del impacto presupuestal en Colombia de la prueba de HPV con genotipificaciÃ³n comparada con la citologÃ¡a. <i>Biomedica</i> , 2022, 42, 290-301.	0.7	1

#	ARTICLE	IF	CITATIONS
943	Professional qualifications of medical affairs pharmaceutical physicians and other internal stakeholders in the pharmaceutical industry. F1000Research, 0, 11, 813.	1.6	0
944	The necessity of continuing cervical cancer screening of elderly Korean women aged 65 years or older. Diagnostic Cytopathology, 2022, 50, 482-490.	1.0	1
945	Assessing Intersectional Disparities in Cervical Cancer Screening by Disability Status, Race, and Ethnicity. , 2022, 1, 100019.		1
946	Clinical value of the ThinPrep cytologic test with E6/E7 mRNA detection for cervical cancer screening in disease diagnosis. Diagnostic Cytopathology, 0, , .	1.0	1
947	Pap smear outcomes in elderly women living with HIV and HIV-negative matched controls. International Journal of STD and AIDS, 2022, 33, 954-962.	1.1	1
948	Gaps in the screening process for women diagnosed with cervical cancer in four diverse <scp>US</scp> health care settings. Cancer Medicine, 2023, 12, 3705-3717.	2.8	3
949	Cervical cancer management in Zimbabwe (2019–2020). PLoS ONE, 2022, 17, e0274884.	2.5	4
950	Current diagnostic tools for HPV. , 2022, , 99-118.		0
951	Disparities in Diagnosis and Treatment of Cervical Adenocarcinoma Compared With Squamous Cell Carcinoma: An Analysis of the National Cancer Database, 2004–2017. Journal of Lower Genital Tract Disease, 2023, 27, 29-34.	1.9	6
952	Secondary Prevention of Cervical Cancer: ASCO Resource–Stratified Guideline Update. JCO Global Oncology, 2022, , .	1.8	8
953	Economic Evaluations of HPV Vaccination in Targeted Regions of Low- and Middle-Income Countries: A Systematic Review of Modelling Studies. International Journal of Women's Health, 0, Volume 14, 1315-1322.	2.6	1
954	Association of Physician Densities and Gynecologic Cancer Outcomes in the United States. Obstetrics and Gynecology, 2022, 140, 751-757.	2.4	1
956	Electrochemical immunosensor for ultrasensitive detection of human papillomavirus type 16 L1 protein based on Ag@AuNPs-GO/SPA. Analytical Biochemistry, 2023, 660, 114953.	2.4	5
957	Methylation biomarkers for early cancer detection and diagnosis: Current and future perspectives. European Journal of Cancer, 2023, 178, 91-113.	2.8	18
959	Rising to the De-escalation Challenge: Multilevel Change Needed to Align Clinical Practice with Cancer Screening Guidelines. Medical Decision Making, 2022, 42, 1045-1047.	2.4	0
960	Factors associated with timely colposcopy following an abnormal cervical cancer test result. Preventive Medicine, 2022, 164, 107307.	3.4	6
961	A study protocol for a cluster randomized pragmatic trial for comparing strategies for implementing primary HPV testing for routine cervical cancer screening in a large health care system. Contemporary Clinical Trials, 2023, 124, 106994.	1.8	0
962	Evaluation of triage strategies for high-risk human papillomavirus-positive women in cervical cancer screening: A multicenter randomized controlled trial in different resource settings in China. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2022, 34, 496-509.	2.2	0

#	ARTICLE	IF	CITATIONS
963	Cervical cancer in Nepal: Current screening strategies and challenges. <i>Frontiers in Public Health</i> , 0, 10, .	2.7	8
964	Professional qualifications of medical affairs pharmaceutical physicians and other internal stakeholders in the pharmaceutical industry. <i>F1000Research</i> , 0, 11, 813.	1.6	2
965	Relationship Between Immunohistochemical CD3, CD4, CD5, CD8, and PD1 Staining and Histopathological Diagnosis of Cervical Lesions in Patients With Abnormal Colposcopic Findings. <i>Cureus</i> , 2022, , .	0.5	0
966	Potential effects of age-based changes in screening guidelines on the identification of women at risk for developing cervical cancer. <i>Cancer Prevention Research</i> , 0, , .	1.5	0
967	Analysis of Deep Learning Architecture-Based Classifier for the Cervical Cancer Classification. <i>Lecture Notes in Electrical Engineering</i> , 2023, , 263-273.	0.4	0
968	Could HPV Type 33 Be More Risky Than We Thought?. <i>International Journal of Surgical Pathology</i> , 2023, 31, 4-10.	0.8	1
969	Impact of human papillomavirus vaccine on cervical cancer epidemic: Evidence from the surveillance, epidemiology, and end results program. <i>Frontiers in Public Health</i> , 0, 10, .	2.7	2
970	SERVÄ°KAL Ä°NTRAEPÄ°TELYAL LEZYONLARDA VE YÄ°KSEK RÄ°SKLÄ° HPV TÄ°PLERÄ°NDE SERVÄ°KAL KOLPOSKOPÄ°NÄ°N YERÄ°. Kocatepe TÄ°p Dergisi, 2023, 24, 43-48.	0.1	0
971	Caregivers with Cancer Patients: Focus on Hispanics. <i>Cancers</i> , 2023, 15, 626.	3.7	4
973	Management of Intraepithelial Lesions of the Cervix. , 2023, , 1-16.		0
974	Cervical High-Grade Squamous Intraepithelial Lesion Burden and Standard of Care Treatment Effectiveness and Safety in the United States, 2008â€“2018: The EACH-WOMAN Project. <i>Journal of Lower Genital Tract Disease</i> , 2023, 27, 105-112.	1.9	2
975	A Review of Deep Learning Methods in Cervical Cancer Detection. <i>Lecture Notes in Networks and Systems</i> , 2023, , 624-633.	0.7	0
976	Molecular markers predicting the progression and prognosis of human papillomavirus-induced cervical lesions to cervical cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 8077-8086.	2.5	3
978	Role of microRNAs in glycolysis in gynecological tumors (Review). <i>International Journal of Oncology</i> , 2023, 62, .	3.3	1
980	Cervical Cancer Screening in Women Aged Older Than 65 Years. <i>Journal of Lower Genital Tract Disease</i> , 2023, 27, 207-211.	1.9	0
981	Cervical Cancer Prevention Knowledge (Cckp-64) among Female Students in Novi Sad, Serbia during COVID-19 Pandemic. <i>Healthcare (Switzerland)</i> , 2023, 11, 1400.	2.0	1
982	Carcinogenesis and management of human papillomavirus-associated cervical cancer. <i>International Journal of Clinical Oncology</i> , 2023, 28, 965-974.	2.2	3
983	Factors associated with shorter-interval cervical cancer screening for young women in three United States healthcare systems. <i>Preventive Medicine Reports</i> , 2023, 35, 102279.	1.8	0

#	ARTICLE	IF	CITATIONS
984	Patterns of cervical cancer screening follow-up in the era of prolonged screening intervals. <i>Gynecologic Oncology</i> , 2023, 175, 53-59.	1.4	0
985	The time has come to implement primary human papillomavirus screening for cervical cancer in the United States. <i>Cancer</i> , 2023, 129, 2765-2768.	4.1	4
986	Cervical cancer prevention in the United States“where we've been and where we're going: The American Cancer Society Primary HPV Screening Initiative. <i>Cancer Cytopathology</i> , 2023, 131, 747-750.	2.4	1
987	Screening Guidelines and Programs for Cervical Cancer Control in Countries of Different Economic Groups: A Narrative Review. <i>Cureus</i> , 2023, , .	0.5	2
988	Diagnostic value of high-risk HPV other than type 16/18 in high-grade cervical neoplasia among cytology-negative women: A multicenter retrospective study. <i>Cancer Medicine</i> , 2023, 12, 14794-14805.	2.8	2
989	Testing for viral DNA integration among HPV-positive women to detect cervical precancer: An observational cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2024, 131, 309-318.	2.3	3
990	Current approaches in the diagnosis, treatment and prevention of HPV-associated cervical diseases: practical recommendations. A review. <i>Gynecology</i> , 2023, 25, 245-250.	0.4	0
991	Cervical Precancerous Lesions and Associated Factors Among Women Screened in Two Hospitals in the City of Douala, Cameroon. <i>Cureus</i> , 2023, , .	0.5	0
993	Knowledge about cervical cancer risk factors and human papilloma virus vaccine among Saudi women of childbearing age: A community-based cross-sectional study from Saudi Arabia. <i>Vaccine: X</i> , 2023, 15, 100361.	2.1	1
994	The relationship of immunohistochemical SOX-2 staining with histopathological diagnosis in patients with abnormal colposcopic findings. <i>Histochemistry and Cell Biology</i> , 0, , .	1.7	0
995	The Association of Cervical Cancer Screening With Disability Type Among U.S. Women (Aged 25“64) <i>Tj ETQq0 0.0 rgBT /Overlock 10</i>	3.0	0
996	Preferential Tissue Sites of Different Cancer-Risk Groups of Human Papillomaviruses. <i>International Journal of Molecular Sciences</i> , 2023, 24, 13151.	4.1	0
997	Cancer Vaccine Therapeutics: Limitations and Effectiveness“A Literature Review. <i>Cells</i> , 2023, 12, 2159.	4.1	9
998	Public Health Approach in the Elimination and Control of Cervical Cancer: A Review. <i>Cureus</i> , 2023, , .	0.5	1
999	DNA methylation as a triage marker for colposcopy referral in HPV-based cervical cancer screening: a systematic review and meta-analysis. <i>Clinical Epigenetics</i> , 2023, 15, .	4.1	2
1000	Diagnostic value of high-risk HPV E6/E7 mRNA in patients with ASCUS. <i>BMC Women's Health</i> , 2023, 23, .	2.0	0
1001	Colposcopy referral rates post-introduction of primary screening with human papillomavirus testing: evidence from a large British Columbia cohort study. <i>The Lancet Regional Health Americas</i> , 2023, 26, 100598.	2.6	1
1002	Knowledge, Attitudes and Behaviors of Clients Regarding Cervical Cancer Screening at Gynecology Consultations of the University Hospital of Cocody. <i>Journal of Obstetrics and Gynecology of India</i> , 0, , .	0.9	0

#	ARTICLE	IF	CITATIONS
1003	Quality of cancer screening at the medical check-up stages. Profilakticheskaya Meditsina, 2023, 26, 57.	0.6	1
1004	Surgical Treatment for Early Cervical Cancer in the HPV Era: State of the Art. Healthcare (Switzerland), 2023, 11, 2942.	2.0	0
1005	Increasing the take-up of public health services: An at-scale experiment on digital government. Journal of Public Economics, 2023, 227, 104975.	4.3	0
1006	Cancer Screening in the Older Adult. , 2023, , 1-25.		0
1007	Prevalence of abnormal pap smears in the western region of Saudi Arabia from 2010 to 2022. CytoJournal, 0, 20, 44.	1.7	0
1008	Guidelines for cervical cancer screening in China. Gynecology and Obstetrics Clinical Medicine, 2023, 3, 189-194.	0.5	0
1009	Inflammatory cytokines and a diverse cervicovaginal microbiota associate with cervical dysplasia in a cohort of Hispanics living in Puerto Rico. PLoS ONE, 2023, 18, e0284673.	2.5	0
1010	Management of Intraepithelial Lesions of the Cervix. , 2023, , 63-78.		0
1011	Cytological features of human papillomavirusâ€infectected immature squamous metaplastic cells from cervical intraepithelial neoplasia grade 2. Journal of Medical Virology, 2023, 95, .	5.0	0
1012	Application value of TCT and HPV in the Diagnosis of Cervical Lesions. Advances in Clinical Medicine, 2023, 13, 20042-20047.	0.0	0
1014	A case report of lung metastasis in a cervical cancer presenting as a consolidation. Radiology Case Reports, 2024, 19, 1144-1148.	0.6	0
1015	High rate of non-vaccine targeted high-risk HPV genotypes circulate among women in Eastern Ethiopia. Scientific Reports, 2024, 14, .	3.3	1
1016	Colposcopy Image Classification using Fuzzy Min-Max Neural Network. , 2023, , .		0
1017	A Comparative Study of Ovarian Cancer Prediction Using Machine Learning Method. , 2023, , .		0
1018	Knowledge regarding human papillomavirus and cervical cancer prevention among medical students from Chulalongkorn University in Thailand. BMC Women's Health, 2024, 24, .	2.0	0
1019	Cancer Screening in the Older Adult. , 2024, , 801-825.		0
1020	Association of Maternal Cervical Cancer Screening Adherence with Adolescent HPV Vaccination Among Adolescent-Mother Pairs. Journal of Community Health, 0, , .	3.8	0
1021	Clinical and economic rationale for cervicalcancer screening program. Literature review. Hirurg, 2024, , 61-68.	0.1	0

#	ARTICLE	IF	CITATIONS
1022	Evaluation of human papillomavirus type 16 viral load and genome physical status in Iranian women with cervical disease. Molecular Biology Reports, 2024, 51, .	2.3	0